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This dissertation is a sequential examination of the epidemiology and 
pathogenetic mechanism of tardive dyskinesia (TD) which is a severe 
movement disorder that affects 20-50% of patients receiving long-term 
antipsychotic treatment.  We first established the extent of this problem 
among a population of 602 Chinese and Malay patients with schizophrenia. 
All subjects were diagnosed to have schizophrenia according to DSM-IV 
criteria. Dyskinesia was assessed by the Abnormal Involuntary Movement 
Scale (AIMS) and examination over time enabled us to make a definitive 
diagnosis of persistent TD based on an operationalized criteria. We found 
high rates of TD: 40.6 % among the Chinese and 29.0 % among the Malays. 
The rate for our Chinese patients was higher than previously reported for 
Chinese subjects, and this finding refute earlier suggestions by other 
investigators that Chinese were at lower risk of developing TD. We also found 
that advanced age and smoking increase the risk of TD.  
There were notable exceptions to other reported findings: we found no 
association with gender, diabetes mellitus, nor with higher fasting blood sugar 
levels. The latter was determined through an oral glucose tolerance test done 
on 108 patients.  
We proceeded to examine certain aspects of the 2 predominant hypotheses 
of TD. The first is the neurotoxic hypothesis and the role that iron may play in 
this mechanism. We compared the serum iron, ferritin and total iron binding 
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capacity (TIBC) of 86 patients with TD and 108 patients without TD. We found 
no association between peripheral iron indices and TD.  
The second hypothesis is the dopaminergic hypersensitivity hypothesis. As 
there is also evidence of a genetic basis to TD, we examined the association 
of certain polymorphisms of the genes which may be involved in the 
pharmacodynamic and pharmacokinetic aspects of antipsychotics and which 
may lead to a state of nigrostriatal dopaminergic overactivity. Using a 
candidate gene approach, we examined the Ser311Cys polymorphism of the 
D2 receptor (DRD2), the Ser9Gly polymorphism of the D3 receptor (DRD3), 
the insertion/deletion polymorphism in the promoter region of the serotonin 
transporter gene (5-HTTLPR), the T102C polymorphism of the 5-HT2A 
receptor gene, and the C→A polymorphism of the CYP1A2 gene. Of these, 
we found an association between TD and the Ser9Gly polymorphism of the D3 
receptor (DRD3), and the T102C polymorphism of the 5-HT2A receptor gene. 
We have identified a number of risk factors for TD which could help identify 
those at risk and enable clinicians to make a more informed decision with 
regards to the type of antipsychotics to prescribe, and to exercise greater 
vigilance for these patients. Further, our findings may putatively form the basis 
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This dissertation comprises a series of studies carried in the 
Woodbridge Hospital which is only state mental institute in Singapore, and is 
the principal treatment centre for those with severe mental illnesses like 
schizophrenia. In 1999, a survey carried out among 534 inpatients with 
schizophrenia in Woodbridge Hospital found that 59% of the patients were 
receiving two or more antipsychotic medications and at significantly higher 
doses than those just receiving one antipsychotic medication, with only 1% of 
the patients receiving atypical antipsychotic. The reason for this low usage of 
second generation antipsychotic is largely economic, and this reason 
continues to prevail to this day. The pervasive use of multiple antipsychotics, 
and marked underutilisation of atypical antipsychotics are issues of concern. 
A corollary of this, and as well as a potential cause for concern, is the extent 
of the side effects resulting from this pattern of drug use. One of the most 
severe of such side effects would be tardive dyskinesia.  As many of the 
patients in this particular hospital are on long term medication, we had 
anticipated that this problem would be pervasive but just how considerable 
was yet unknown and we felt that it was important to establish the extent of 
this severe side effect. Tardive dyskinesia would be, in the advent of the 
second generation antipsychotcs, not an acceptable consequence of 
treatment. However, this may also need to be balanced with the emerging 
problem of metabolic syndrome caused by some of these second generation 
antipsychotics which would also have dire long-term complications including 
increased disabilities, mortality and health costs. 
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What started out as an epidemiological study of the prevalence of 
tardive dyskinesia (TD) led to more questions and the attempt to answer 
some of these questions is contained in this dissertation. 
This dissertation is a sequential study of a number of postulated risk 
factors for tardive dyskinesia TD. 
The first paper of this dissertation is a review of the extant literature on 
the epidemiology of TD. It also identifies the lacunae in our knowledge of TD - 
some of these would be investigated in the subsequent part of the 
dissertation.   
The second paper establishes the prevalence of TD among Chinese 
and Malay patients with schizophrenia and investigates some of the putative 
sociodemographic risk factors implicated in TD. In particular, it examines the 
assertion that Chinese are at lower risk of developing TD.  
The subsequent papers are a series of studies on particular factors that 
may be involved in the pathophysiology of TD. Thus, the third paper examines 
the role of impaired glucose tolerance, the fourth is on the role of iron. The 
fifth and final paper is an investigation into the genetics of the 
pharmacokinetic and pharmacodynamic aspects of antipsychotics and their 



































In this chapter, an overview of the epidemiology of tardive dyskinesia 
(TD), its prevalence and incidence, and the putative risk factors are examined.  
While there is an extensive literature on the epidemiology of TD, the findings 
are varied, even though consensus has emerged on many aspects.  The 
diversity of the epidemiological findings call for an explanation, and many 
possible reasons can be suggested.  Importantly, the very definition of TD has 
been the subject of much debate. While the movements that are characteristic 
of TD are usually choreoathetoid, antipsychotic-induced tardive movements 
may also be dystonic, akathisic, tic-like, myoclonic or tremorous in their 
manifestation.  This has led to a debate between the ‘lumpers’ and ‘splitters’, 
i.e. those who include all these different movements within the rubric of TD, 
and those who make a distinction between TD and other tardive syndromes 
such as tardive dystonia, tardive akathisia, or tardive tics. Another issue is the 
time factor of the condition as implied by the term “tardive” which is derived 
from the French word “tardif” meaning “late”.  Until the widely accepted criteria 
proposed by Schooler and Kane (1) in 1982 which specified a time criteria for 
persistent TD (3 months) and chronic TD (6 months), there had been a lack of 
standardisation which make comparisons among studies problematic. These 
criteria also specify that a definite research diagnosis of TD is made only if 
movements of moderate severity are present in one or more body parts, or of 
mild severity in two or more body parts. This would exclude cases with mild 
movement in one body area and which Jeste and Wyatt (2) have proposed to 
be sufficient to diagnose TD.  
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Other factors that may confound any epidemiological study include the 
following: the temporal aspect of TD (fluctuating course of the condition); pre-
existing spontaneous dyskinesia; differences in assessment (nominal vs 
ordinal criteria, use of different rating instruments, single or multiple 
assessments); differences in treatment practices (type, dosage and duration 
of antipsychotic treatment, concurrent medication e.g. anticholinergic drugs, 
whether patients are currently on antipsychotic at time of assessment, etc.); 
and the heterogeneity of the patient population (age, gender, ethnicity, 
duration of illness, exposure to medications, diagnosis, the presence of 
pseudoparkinsonism masking the disorder).  In a critical examination of the 
literature, all these factors need to be taken into consideration.  While it is not 
possible to critically examine all the studies in this chapter, we take a 




In two key review articles (3,4) that examined the prevalence rates of 
TD in the diverse studies, the authors used the retrospective “pooled data” 
method where frequency figures from selected primary studies were pooled 
and a mean was calculated. In a review of 56 studies which spanned from 
1959 to 1979, Kane and Smith (3) reported point prevalence rates ranging 
from 0.5% to 65%, with an average point prevalence of 20%. In a later review 
of 76 published studies, Yassa and Jeste (4) reported an overall prevalence of 
24% among a total of 39,187 patients. The clinical significance of these 
   6 
  
figures is limited as they were derived from studies that differed in 
assessment criteria, methodology and population characteristics.    
The study by Woerner et al. (5) attempted to address some of the 
previous methodological issues. The overall prevalence of TD in 
antipsychotic-treated individuals in this study was 23.4%, of which 3.8% had 
another medical illness that might have had an aetiological role, thus giving a 
conservative prevalence rate of 19.6%.  The rate varied with the setting, being 
13.3% at a voluntary hospital with a young population, 23% in a Veterans 
Administration hospital and 36% in a state hospital.  In the same study, when 
a group of patients with no evidence of TD was withdrawn from antipsychotic 
drugs and examined weekly for 3 weeks, 34.0% developed emergent 
dyskinesia. 
Another large scale study by Muscettola et al. (6) reported a prevalence rate 
of 19.1% among 1651 psychiatric patients. While both studies used the 
operationalised criteria of Schoolner and Kane, it also meant that those with 
mild dyskinetic movements were excluded.  
 
Spontaneous Dyskinesia 
Hyperkinetic involuntary movement also occurs in some individuals 
without any known causes. Prevalence rate of 0.8%, 6.0% and 7.8% for 
spontaneous dyskinesia have been reported in the 6th, 7th and 8th decades 
of life respectively in otherwise healthy subjects (7). Kane et al. (8) reported a 
rate of 4.0% in healthy elderly (mean age 73 years) subjects. Prevalence is 
higher in psychogeriatric patients, especially in those with dementia (9). Most 
of the studies were performed in elderly populations, owing to the observation 
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that spontaneous dyskinesias are more common in the elderly. However, one 
study (10) found that 12.6% of antipsychotic-naive young subjects (aged 3 – 7 
years) had at least a rating of “mild” on the Abnormal Involuntary Movement 
Scale (AIMS), and 4.1% fulfilled the Schooler and Kane criteria for TD.  
The presence of spontaneous dyskinesias in psychiatric populations 
confounds the true prevalence rate of antipsychotic-induced TD. Studies have 
reported that the prevalence of these spontaneous movements is higher 
among antipsychotic-naïve patients with schizophrenia (Table 1) than older 
non-psychiatric patients (11-13) and patients with other psychiatric diagnoses 
(14,15) – suggesting a particular association with schizophrenia.  
Age is a risk factor as well. Reviewing 14 studies which reported 
prevalence rates of spontaneous dyskinesia among antipsychotic-naïve 
schizophrenic patients, Fenton (15) found a positive correlation with age: 
12.0% among schizophrenic patients with mean age of 30 years or younger, 
25.0% among those between 31 to years, and 42.0% among those over 60 
years.  
The pathophysiology of such spontaneous dyskinesia is unknown. The 
evidence, though not very robust, suggests that these spontaneous 
movements are found more significantly among antipsychotic-naive 
schizophrenic patients than antipsychotic-naïve patients with other diagnoses 
(15).  It has been suggested that this abnormality of movement is intrinsic to 
the pathophysiology of schizophrenia (16) and Waddington and Crow (9) have 
suggested it may be a manifestation of brain damage. Whether the presence 
of spontaneous dyskinesia will worsen or accentuate antipsychotic-induced 
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TD remains to be elucidated, as there is no study to date that has 
prospectively examined this relationship.   
 
INCIDENCE   
Given the difficulties inherent in prevalence estimates, it has been 
much more rewarding to examine the incidence of TD, and the salient studies 
have been summarized in Table 2. The varying rates probably reflect 
differences in methodologies and samples, as discussed previously.   
Notwithstanding the difficulties, these studies suggest that the cumulative 
incidence of TD increases with increasing duration of antipsychotic treatment 
at the rate of about 3-5% per year for the first several years, to reach a 
plateau at about 20-25%, but new cases continue to occur many years after 
drug initiation.  It is difficult to identify a point in time after which the risk 
decreases. The plateau is accounted for by cases that remit while new cases 
are being added.  The two largest prospective studies from Yale (17) and 
Hillside Hospital, New York (18) provided sizable patient populations that 
were followed up for 5 and 7 years respectively. However, both studies 
examined patients who had been psychiatrically unwell and treated with 
antipsychotics for some time prior to study onset, with the implication that any 
past history of TD could not have been excluded. 
Of great clinical interest is the incidence of TD in drug-naïve patients 
with a first episode psychosis. Such studies have the advantages of a 
“cleaner” cohort without the likelihood of past history of TD. The prospective 
medication and clinical data also enable a more robust examination of the 
relationship of TD with other factors.  In a prospective study (19) of 118 
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patients with first episode schizophrenia (mean age 25.2 years), the 
cumulative incidence of TD was 4.8% in the first year, 7.2% in year 2, and 
15.6% after 4 years. The incidence is many times higher in elderly individuals 
with reported cumulative annual incidence of TD of more than 25% (20,21).  
Jeste et al. (22) reported that among older patients (mean age of 66.2 years), 
the risk of TD is high even after a short duration of typical antipsychotic 
treatment, with a mean cumulative incidence of TD of 3.4% and 5.9% after 1 
and 3 months of treatment, respectively.  
The advent of atypical antipsychotics is likely to have an impact on the 
future incidence of TD. The preliminary data with the atypical antipsychotics 
indicate a lower risk for TD with an expectant fall in the incidence of TD. 
However, most of the studies to date are of relatively short follow-up, 
preventing longer term predictions regarding the development of TD with 




Advanced age is the most consistently established risk factor for TD, 
and there appears to be a linear correlation between age and both the 
prevalence and severity of TD (24). High rates have almost invariably been 
reported in elderly patients on antipsychotics. Yassa et al. (25) followed up 99 
geriatric psychiatric inpatients for 5 years and found that 30% developed TD 
at the end of this time. In another prospective study of 266 patients with a 
mean (SD) age of 65.5 (12.0) years, the cumulative incidence of TD was 26%, 
52% and 60% after 1, 2, and 3 years, respectively (20). This contrasts sharply 
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with a prospective study on 850 young adults (mean age of 29 years), where 
the cumulative incidence of TD was 5%, 19% and 26% after 1, 4, and 6 years 
of treatment (26).  
TD in the elderly is also more likely to affect the oro-buccal-facial-
lingual musculature, develop early in the course of antipsychotic treatment 
and be irreversible. The elderly also show a higher frequency of abnormal 
movements from other causes (27). The underlying mechanism mediated by 
aging is unclear. Proposed hypotheses include interactions with drug-induced 
changes in the receptors in the stratium and age-related degenerative 
changes in the nigrostriatal system (11). Older patients are also more likely to 
develop diabetes mellitus and cerebrovascular insults which may in part 
account for the increased vulnerability for TD (28). In a review of clinical and 
animal studies, Waddington et al. (29) concluded that age-related and 
disease-related structural brain changes might be associated with TD. Aging 
is also associated with less efficient metabolism and excretion of drugs, and 
these age-related pharmacokinetic changes may lead to exposure to higher 
blood levels of antipsychotic medications (30).  
While TD has been reported in children and adolescents, it is 
considered to be uncommon (31), but adequate epidemiological studies are 
few. Rates of withdrawal-emergent dyskinesia of 8% (32) and 51% (33) have 
been reported in two studies of children on long-term antipsychotics.  
 
Gender 
A number of studies have indicated a higher risk for women to develop 
TD (34-37), but other studies have either failed to find an association (38) or 
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have conversely reported a higher risk for men (39). In the 75 studies 
reviewed by Yassa and Jeste (4), only six studies reported rates stratified by 
age groups which indicated excess risk for women aged 51 years or older, 
and TD was evenly distributed by gender in the lower age groups. This 
suggests a possible interaction with age, with women having a higher risk in 
the elderly age group. Estrogen has been suggested to have a protective 
antidopaminergic effect and the decline in the levels of this hormone at 




In a review of studies from 15 different countries involving 33,000 
antipsychotic-treated patients, Kane et al. (40) found wide variation in TD 
rates among countries. Yassa and Jeste (4) noted that across studies 
undertaken in four continents reviewed by them, the lowest prevalence of TD 
was reported from Asia : a Shanghai study reported a point prevalence of 
8.4% (41) which was close to a Hong Kong study with a rate of 9.3% (42) 
while the lowest rate (2.5%) was found in Singapore (43). among Chinese in 
Hong Kong. Suggested lower prevalence rates of TD among Chinese 
subjects from these studies, when compared to studies in Western subjects, 
have led to the suggestion of inter-ethnic differences – possibly genetic - in 
the vulnerability of developing TD (44). A contrary view was expressed by Pi 
et al. (45), who established differing prevalence rates of TD among Chinese 
patients in Beijing, China (8.2%), Hong Kong (19.4%) and Yanji, China 
(18.6%), leading to the suggestion that environmental factors such as differing 
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prescribing patterns are more likely to account for any such differences. 
Unfortunately, environmental, and cultural factors, as well as methodological 
differences in studies conducted in different settings in various countries 
compromise the interpretation of results. A better approach is to study 
different groups within the same setting. Along the same lines, the group of 
investigators at Yale (17,46) found that nonwhite patients (97% of whom were 
African-Americans) were about twice as likely to develop TD even after 
adjusting for dose and duration of exposure. In their sample of 266 patients 
which included, 215 Caucasians and 32 African American, Jeste and co-
workers (20) reported an annual cumulative TD incidence rate of 26% in 
Caucasians and 48% in African Americans. The two groups did not differ 
significantly in daily antipsychotic dose or duration of treatment.  
Of the studies that have examined ethnicity, it appears that African 
Americans may have a heightened vulnerability for TD. However, it would be 
premature to come to any conclusion about the role of ethnicity in TD. The 
considerable methodological issues mentioned may give rise to conflicting 
results. There is also the problem of making an accurate assessment of 
ethnicity, especially in a multiracial society (47). Even when a significant 
relationship is demonstrated, the association may be caused by genetic 
factors and/or environment factors like diet, smoking, alcohol consumption, 
and medication types and dosage (48). 
  
Antipsychotic drugs   
 While there has always been a suspicion that antipsychotic drug dose 
is important in the risk of TD, empirical evidence for this has been lacking, 
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although recent longitudinal studies have provided empirical support for 
higher doses increasing the risk (16,38). It is possible that in previous studies, 
this dose effect was masked by the historical trend towards the use of higher 
antipsychotic doses, an approach which is giving way more recently to lower 
doses (49). Taking dose and duration of use together, total antipsychotic load 
is considered to be a risk factor.   
The data in relation to antipsychotic blood levels and the development 
of TD are inconsistent. While one study (50) suggested a positive correlation 
between antipsychotic plasma levels and TD, another study found no such 
relationship (51). 
 Drug type also remains controversial. At present, there is no convincing 
evidence that once drug dosage has been accounted for, there are 
differences between conventional antipsychotic in the risk of TD; similarly, 
there is no empirical evidence that depot antipsychotics are more likely to 
cause TD (11). Studies of this issue are limited by the use of polypharmacy 
and the common occurrence that many patients received different 
antipsychotics at different times. 
Most of the atypical antipsychotics have in common a high serotonin to 
dopamine receptor blockade ratio in the brain, and this high serotonergic 
blockade is thought to play a role in reducing acute extrapyramidal symptoms 
(52) which have been suggested to be a risk factor of the subsequent 
development of TD. A corollary would be that these atypical antipsychotic 
have a lower liability to cause TD. While there are anecdotal reports of TD 
with risperidone (53,54), olanzapine (55,56) and quetiapine (57), there is no 
convincing report of TD with clozapine monotherapy and this may indeed be 
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the safest drug (11, 58). Clozapine may be successful in improving TD and 
present a lower risk for TD (59), and has therefore been proposed as a 
treatment for TD (60,61).  However, it is unclear whether it helps some 
patients with TD by merely permitting spontaneous remission; or whether in 
fact, it represents active treatment. A review (63) on 11 studies that lasted 1 
year or longer indicated that second-generation antipsychotics (risperidone, 5 
studies; olanzapine, 2 studies; quetiapine, 2 studies, amisulpride 1 study, and 
ziprasidone 1 study) have a lower risk for tardive dyskinesia. In adult and 
elderly patients, the incidence of TD was about one-fifth of the risk observed 
with first-generation antipsychotics. 
The practice of drug holidays, which was once advocated to reduce the 
total antipsychotic load in an individual, is now believed to be either ineffective 
or, in fact, harmful by increasing the risk of TD (63). Brief intermittent or 
targeted treatment may, however, offer an advantage by reducing the 
exposure to antipsychotics but it should be further investigated and balanced 
against any increased risk of schizophrenic relapse (64). 
  
Other drugs   
 The role of anticholinergic drugs in the development of TD remains 
controversial. Anticholinergic drugs are known to exaggerate TD or make 
latent TD become manifest, but there is no convincing evidence they are risk 
factors for TD per se (11), however, in a population of 1745 patients, 
Muscettola et al. (6) reported that the combined use of antipsychotic and 
anticholinergic drugs was associated with a significantly increased rate of TD. 
Patients with extrapyramidal symptoms are more likely to receive 
15 
  
anticholinergic medication, and it may be the presence of these symptoms 
(which usually precede the onset of TD) that is, in fact, a predictor of TD 
vulnerability. 
The concurrent administration of lithium in affective disorder could 
possibly reduce the risk of TD, as suggested by animal data (65). However, 
subsequent animal studies (66) showed that lithium augmented the 
amphetamine effect on the development of dopamine receptor 
supersensitivity, and this is consistent with other clinical reports suggesting 
that lithium could reinduce or exacerbate the vulnerability for TD (67-69). 
 A review of 71 case studies (70) indicates that there seems to be a 
causal relationship between selective serotonin reuptake inhibitors (SSRIs) 
and extrapyramidal syndromes, including TD. There is no prospective study 
that has systemically examined the incidence of treatment-emergent TD with 




Genetic predisposition to TD has been suggested from family studies 
that show concordance for TD among first degree relatives of patients with TD 
also treated with antipsychotics (72,73). As the hypothesis for the 
pathophysiology posits a state of dopamine receptor hypersensitivity from 
chronic antipsychotic treatment, an obvious candidate gene is the D2 receptor 
gene. Chen et al. (74) reported a significant association between the 
dopamine D2 receptor gene (DRD2) and TD however this was not replicated 
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by other investigators (75,76). Dopamine D3 receptor polymorphism has been 
implicated as a vulnerability factor in some reports (77,78), but not all (75). 
The interindividual variation in vulnerability for TD also suggest a 
pharmacogenetic component. A particular line of investigations has focused 
on the genetic polymorphism of the cytochrome P450 isoenzyme, 
debrisoquine 4-hydroxylase (CYP2D6). The poor metabolizer (PM) 
phenotype, characterized by lack of CYP2D6 activity, is caused by a number 
of mutations (79) that may confer a greater vulnerability for concentration-
dependent side-effects, including TD. Andreassen et al. (80) reported an 
increased (but not significant) susceptibility of PM to TD. Ohmori et al. (81) 
also found a positive association between TD and a particular PM 
(CYP2D*10) allele but not with the CYP2D6*2 allele (82). Heterozygous 
carriers for other mutations (CYP2D6*3, CYP2D*4 and CYP2D6*5) may also 
be more vulnerable to developing TD (83). 
 
Diabetes Mellitus  
There is some evidence that diabetes increases the risk of both 
spontaneous dyskinetic movements (21%) and TD (79% in diabetics vs. 53% 
in non-diabetics) (83).  Woerner et al. (85) reported a risk ratio of 2.3 for 
diabetics exposed to antipsychotics compared to similarly treated non-
diabetics, with the risk greater in aged diabetics.  Fasting blood glucose has 
been reported to be higher among those with TD (86), and Schultz et al. (87) 
reported that patients with impaired glucose tolerance had higher mean AIMS 
scores (although not reaching statistical significance), with an association 
between the magnitude of the fasting insulin level and abnormal movements. 
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The pathophysiology of this association between hyperglycemia and TD is 
unknown. Glucose induced dopamine sensitivity has been suggested in 
animal studies (88) and a possible genetic factor may also be involved, as 
suggested by a report which found greater incidence of diabetes in relatives of 
patients with TD (89). 
 
Neuropsychiatric disorder 
A number of investigators have commented on a higher relative 
incidence of TD in patients with affective disorder treated long-term with 
antipsychotics (18,90,91), but this finding is inconsistent, and may apply to 
early- and not late-onset TD (92). Kane et al. (18) reported incidence figures 
of 26% for affective and schizoaffective disorders, and 18% for schizophrenia. 
A positive family history of affective disorder in schizophrenic patients has 
also been associated with increased risk of antipsychotic-induced TD (93). 
Depression may, furthermore, produce a state-dependent exacerbation of TD 
(94), while mania may lead to the reverse (95). 
 Whether schizophrenia increases or decreases the risk for TD is not 
known.  The similarity between the spontaneous dyskinesias of schizophrenia 
and TD has been suggested as evidence for schizophrenia as a risk factor, 
but the opposite has also been suggested (96). Within schizophrenia, those 
with the negative syndrome, or evidence of cognitive impairment and 
neurological deficits, are reported to be more at risk (97), and the presence of 
TD indicates a poorer prognosis for schizophrenia.    
The presence of brain damage (as evidenced by epilepsy, head 
trauma, dementia, etc.) has been suggested as a risk factor. High rates (34%) 
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have also been reported in antipsychotic-treated individuals with mental 
retardation (98,99). Yassa et al. (100), in a study of 300 patients who had 
organic mental disorders and were treated with antipsychotics, found that brain 
damage was a risk factor, but the evidence is inconsistent (30). TD is known to 
develop in patients with Tourette’s Disorder treated with antipsychotics, but the 
prevalence rate, though not well studied, is likely to be lower than that seen in 
schizophrenia, possibly because of the youth of the patients and the lower 
antipsychotic doses used (96). 
Extrapyramidal side-effects 
 Several reports have suggested that early extrapyramidal side-effects 
(EPS) are a risk factor for the later development of TD. Kane et al. (101) 
reported that patients with a history of severe EPS were 2.3 times more likely 
to develop TD than those without such a history. Two prospective studies of 
elderly patients (20,21) found that the presence of EPS early in treatment was 
a predictor of TD. In contrast, Chatterjee et al. (102), in a prospective study of 
89 antipsychotic-naïve patients with first-episode schizophrenia, did not find 
any correlation with EPS and TD. However, the sample comprised young 
adults and the period of follow-up (234 weeks) may have been insufficient for 
the risk to manifest itself. The Yale group (17) also found a relationship 
between TD and history of EPS, but the clinical history was obtained 
retrospectively and, therefore, may have not identified all cases of TD.   
The putative role of EPS is in keeping with the supersensitivity 
hypothesis of TD, suggesting a vulnerability to extrapyramidal symptoms in 
these patients.  The basis of this sensitivity to ‘basal ganglia disease’ is not 




Electroconvulsive therapy (ECT) 
A history of ECT has been suggested as a predictor for TD vulnerability 
(100), although other studies showed no such association (11,103,104) and 
one study indicated a lowering of risk (105). A history of ECT may be an 
epiphenomenon, in that patients who had received ECT could be a subgroup 
with severe mood or “true” mood disorders, the presence of which itself may 
be a risk factor for TD (28).  
 
Substance use 
Two studies have reported a positive correlation between smoking and TD 
(106,107). Menza et al. (108) found a positive association between higher 
antipsychotic doses and smoking, but not between TD and smoking. Alcohol 
abuse has been reported to increase the risk of TD (109-113) with one study 
suggesting a 3-fold increase in risk (113). The use of other psychoactive 
substances especially chronic use of high dose amphetamines may lead to 
dyskinesia (114).  
Alcohol has been suggested to increase the vulnerability for TD 
through its neurotoxic effect, or indirectly by being related to other factors like 
poor compliance and, hence, intermittent exposure (115).  
 
Iron status 
One of the hypotheses for the pathogenesis of TD is that it is due to the 
neurotoxic effects from free radicals, which are the by-products of increased 
catecholamine metabolism caused by D2 receptor blocking medications (116). 
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As iron is a catalyst of free radical damage, it may have a role in free radical-
mediated neurotoxicity, especially in the basal ganglia where both iron levels 
and dopamine levels are high (117). Wirshing et al. (118) found a significant 
positive correlation between serum iron indices (ferritin, iron and total iron 
binding capacity) and AIMS scores in 30 patients with schizophrenia. One 
postmortem report showed extensive iron deposition in the basal ganglia and 
substantia nigra in a man with bipolar affective disorder and persistent TD 
(119). Magnetic resonance imaging (MRI) enables the in vivo assessment of 
brain iron status and one MRI study suggested increased caudate iron levels 
in schizophrenic patients with TD compared to those without (120).  Elkashelf 
et al. (121), on the other hand, found no difference in basal ganglia iron 
between schizophrenic patients with and without TD. Technical problems and 




Oral dyskinetic movement may occur secondary to edentulousness 
(122) but the possible underlying mechanism remains speculative. Two 
studies showed that antipsychotic-treated edentulous patients had more 
severe ratings of TD (123,124). Inferring from the observation that lesions of 
the globus pallidus alter trigeminal sensory-induced reflexive neck muscle 
activity in rats, Sandyk and Kay (124) suggested that edentulousness, by 
disrupting trigeminal proprioceptive input from the oral cavity to the basal 
ganglia, may increase the risk for TD.   
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Issues to be further investigated:  
 There has been significant progress in the understanding of the 
epidemiology of TD and its risk factors, but there are still considerable gaps in 
our knowledge. The issue of inter-ethnic differences needs to be elucidated 
with well-designed studies, preferably by the same investigators, among 
different ethnic groups in the same setting.  
The dopamine receptor supersensitivity hypothesis of TD (125) that 
dominated debate in the 1970s and 80s has a number of limitations. It does 
not explain the observation that supersensitivity in animals is almost invariable 
whereas TD develops only in a fraction of patients, nor does it explain the 
spontaneous occurrence of dyskinesia in many schizophrenic and healthy 
subjects, and the increased risk with age as well as many other host factors. 
Another hypothesized pathogenetic mechanism posits that TD is the 
consequence of antipsychotic-induced neuronal loss, particularly in the 
striatum (116), from production of free radicals and excitotoxicity, both of 
which lead to apoptotic death of neurone. Antipsychotics lead to the 
accumulation of iron in the basal ganglia, which may also be neurotoxic 
through free radical mechanisms (126).  
This dissertation is a systematic investigation of TD among patients 
with schizophrenia and the role of various putative risk factors. The first phase 
was a descriptive epidemiological study which defined the extent of this 
disorder and some of the associated factors in a defined population. Some of 
these factors were further investigated in greater depth – these include the 
role of glucose dysregulation, iron, and genetic factors that could affect the 
pharmacodynamics and pharmacokinetics of antipsychotics. Taking these 
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factors into consideration, a model of the underlying mechanism for TD is 
proposed. The dissertation also discussed the the future direction for 










Table 1.   Prevalence of spontaneous dyskinesia among schizophrenic patients 
 
Authors Population / diagnostic criteria Measurement / criteria Age in yrs, mean (s.d.) Prevalence 
 




AIMS, not blind 24 0 
Chatterjee et al, 1995 (102) First-episode RDC in-patients in acute phase Simpson Dyskinesia Rating 
Scale ≥ 1 on global total 
25.8 (range 16-40) 1% 
Puri et al, 1999 (128) 
 
Antipsychotic-naïve first-episode schizophrenia AIMS≥2 on one or more item 27.2 (8.4) 7% 
Gervin et al, 1998 (129) 
 
Irish, first-episode schizophrenia, DSM III-R AIMS≥2 on one or more item 27.7 (9.7) 7.6% 
Fenn et al, 1996 (130) 
 
DSM-III-R Morocco AIMS, Schooler and Kane 28 (5.3) 14% 
Fenton et al, 1994 (131) Pre-antipsychotic DSM-III or Feighner in-patients Medical record review up to 3 
months following index 
admission 
28 (range 15-55) 
67% ≤ 30 
28% 
Hoffman et al, 1996 (132) 
 
Moroccan, DSM-IV, never treated AIMS, Schooler and Kane 29.6 (6.5) 27% 
Cassady et al, 1998 (133) Subjects with schizophrenia spectrum personality 
 
Maryland Psychiatric Research 
Involuntary Movement Scale>3 





Caligiuri & Lohr, 1993 (134) DSM-III-R male paranoid in-patients AIMS ≥ 1 (minimal) in ≥ 2 body 
aresa 
37.1 (12.2) 14% 
Turner, 1989 (135) Pre-antipsychotic RDC in-patients Case record review Selected from larger sample 
with age at admission of 
roughly 41-45 
29% 
McCreadie & Ohaeri, 1994 
(136) 
Nigerian, DSM-III AIMS, Schooler & Kane criteria 45 (14) 0 
Owens et al, 1982 (137) Chronic in-patients hospitalised > 2 years AIMS ≥ 2 on one or more item 66.7 (11.7) 
(range 29-90) 
53%  
Owens et al, 1982 (137) Chronic in-patients hospitalised > 2 years Rockland Scale ≥ 2 total 66.7 (11.7) 
(range 29-90) 
77% 
Owens & Johnstone, 1980 
(138) 
Feighner, chronic in-patients Examined 70.3 52% 
McCreadie et al, 1996 (139) Indian, DSM IV AIMS ≥ 2 on global scale Tardive dyskinesia group = 75 29% 
McCreadie et al, 1982 (140) Subjects from UK, catchment area AIMS ≥ 2 global 75 29% 
     
Owens, 1985 (141) Feighner and PSE chronic, hospitalised 
continuously ≥ 1 year 
AIMS ≥ 2 on one or more item Not reported 45% 




















































































































1 Elderly neuropsychiatric patients;  2 First-onset schizophrenic patients followed-up 
a Severe tardive dyskinesia only 
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ABSTRACT 
 
Aims: The prevalence of tardive dyskinesia (TD) was studied with the 
Abnormal Involuntary Movements Scale in Chinese and Malay patients with 
schizophrenia and hospitalised in a Singapore state psychiatric institute. We 
also studied the relationship of antipsychotic-induced extrapyramidal side 
effects (EPSE) to TD. 
Method: All subjects were diagnosed to have schizophrenia according to 
DSM-IV criteria. Dyskinesia was assessed by the Abnormal Involuntary 
Movement Scale (AIMS), while extrapyramidal side-effects (EPSE) were 
assessed by the Simpson-Angus Rating Scale (SARS). The cumulative 
duration of antipsychotic exposure as well as current daily dosages were 
obtained. The dosages of neuroleptic medications were converted to 
chlorpromazine equivalents (CPZ eq). 
 Results: Using established criteria, the rates of TD were 40.6 % for Chinese 
and 29.0 % for Malays, higher than previously reported for Chinese subjects. 
Older age and lower current antipsychotic dose were significantly associated 
with TD.  Multivariate analysis, after controlling for other salient risk variables, 
did not show a significant difference in TD prevalence rates between the two 
races.  
Conclusions: Our findings suggest that differences in interethnic rates of TD 
between Chinese, Malays and Westerners are unlikely to exist, and that any 
variation in prevalence is more likely to be determined by age of the study 
population, differences in duration of exposure and dose levels of 
antipsychotic drugs. 
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INTRODUCTION 
Numerous epidemiological studies of TD have been undertaken but 
most have involved western populations. A review of 56 western studies (3) 
reported point prevalence rates ranging from 0.5% to 65%, with an average 
point prevalence of 20%. Yassa and Jeste (4) noted that, across studies 
undertaken in four continents reviewed by them, the lowest prevalence of TD 
was reported in Asia. Studies of homogeneous ethnic groups like the Chinese 
or Malays are, however, scanty. Point prevalence of TD among patients in 
different countries ranged from 8.4% to 27.3% (41-43). Suggested lower 
prevalence rates of TD among Chinese subjects from these studies when 
compared to studies of Western subjects have led some authors to suggest 
inter-ethnic differences – possibly genetic - in the vulnerability to developing 
TD (43,44). However, Pi et al. (45) noting the variance in the rates among 
Chinese in different geographical localities, suggested that environmental 
factors such as differing prescribing patterns were more likely to account for 
any such differences.  
None of the studies of Chinese patients have examined for effects of 
drug-induced parkinsonism which may substantially mask dyskinetic 
movements, and so artefactually lower the prevalence of TD. Additionally, few 
studies have compared the prevalence of TD among ethnic groups in the 
same country by the same investigators, a strategy having the advantage of 
controlling for differences in inter-rater reliability, assessment, diagnostic 
criteria, age of subjects, prescribing practices, (48) and possibly even drug 
dose patterns.    
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This study sought to establish the point prevalence of TD among 
Chinese and Malay patients with schizophrenia in a defined region, and 
examine for any association of TD with antipsychotic-induced extrapyramidal 
side-effects. As older age (24,85,144) gender (4,37) duration of antipsychotic 
treatment (18), exposure to anticholinergic medication (37) and diabetes 
(84,85) have all been reported as risk factors for TD, we also examined for 
associations between these variables and TD among our subjects. 
 
METHOD 
Singapore is an island state in South-East Asia with a population of 3 
million, 77% of whom are Chinese and 14% are Malays. The Chinese are the 
descendants of immigrants from mainland China, while the Malays were 
settlers from peninsular Malaysia and the Indonesian archipelago. 
Woodbridge Hospital is the only state psychiatric hospital in Singapore and is 
the principal treatment centre for those with severe mental illnesses like 
schizophrenia. The majority of patients with schizophrenia are highly likely to 
have received their entire treatment at this hospital which maintains records 
from first contact. It is therefore possible to obtain a reasonably detailed 
lifetime history of patients’ drug treatment.  
We sought to determine the age of onset of treatment initiation, the 
cumulative durations of antipsychotic and anticholinergic medications and 
their current daily dosages through the abstraction of these relevant 
information form the medical records.  We converted dosages of antipsychotic 
drugs to chlorpromazine equivalents (CPZ eq) using standard guidelines 
(145,146) (Appendix A). The only anticholinergic agent used was 
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trihexyphenidyl. Ethnicity of the patients was established by asking the 
patients to state their own ethnicity and their country of birth as well as that of 
their parents. Patients with chart diagnoses of diabetes were identified, and 
those receiving oral hypoglycaemics or insulin treatment were also classified 
as diabetic. 
 Patients hospitalised in the long-stay wards of Woodbridge Hospital 
were recruited. We excluded those with neurological or medical condition or 
on medications that could cause dyskinesia (criterion E of DSM-IV research 
criteria for neuroleptic-induced TD). None of the patients had any history of 
alcohol abuse for at least the past one year. Informed consent was obtained 
from each patient after a detailed explanation of the study. The study was 
approved by the hospital’s Ethics Committee. DSM-IV diagnoses were 
generated by a psychiatrist who reviewed medical record data and, where 
necessary, interviewed the patient. Dyskinesia was assessed by the 
Abnormal Involuntary Movement Scale (AIMS) (147), while extrapyramidal 
side-effects (EPSE) were assessed by the Simpson-Angus Rating Scale 
(SARS) (148). Such ratings were undertaken by three psychiatrists who were 
blind to the clinical and medical histories of the patients, and who had jointly 
assessed a number of patients over three sessions before the start of the 
study. We established inter-rater reliability (intraclass correlation) coefficients 
of 0.86 for the AIMS and 0.82 for the SARS. All the patients received two 
ratings with an interval of at least 3 months between the ratings. Medications 
were kept unchanged during these periods of assessment. The criteria used 
in the diagnosis of TD were those of Schooler and Kane (1). Patients were 
diagnosed to have TD only when two assessments fulfilled the criteria of 
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presence of “moderate” abnormal movements in one or more body areas or at 
least “mild” movements in two or more body areas. Positive EPSE status was 
defined by a total SARS score ≥ 3. 
Statistical methods 
The prevalence of TD in the respective groups was calculated as a 
percentage of subjects surveyed and the associated 95% confidence interval 
(CI) calculated using standard methods. However, for the logistic regression 
analysis, those proportions are expressed relative to each other in terms of 
odds ratios (OR). Univariate logistic regression (149) was used to assess the 
effect of ethnicity and other potential risk factors for TD. In these analyses, the 
ORs were calculated by comparison to a reference group for each risk 
variable. Values of OR > (<)1 indicate an increased (decreased) risk of TD as 
compared to the reference. A logistic regression was performed using 
ethnicity as the dependent variable and variables that were statistically 
significant at the univariate analysis stage (P≤ 0.05): age, duration of 
cumulative antipsychotic exposure, current antipsychotic dose, SARS score, 
EPSE as the covariates. The final model was adjusted for multi-colinearity. 
This provided an estimate of the OR for ethnicity adjusted for the possible 
confounding influences of the other variables in the models. 
 
RESULTS 
Of the 602 patients, 537 (89.2 %) were Chinese and 65 (10.8 %) were 
Malays. There were no significant differences in the gender distribution, 
duration of illness or daily antipsychotic dose between the two ethnic groups 
although the Chinese were older than the Malays (53.4 ± 11.7 vs 49.5 ± 11.0 
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yrs; t = 2.42, df = 67, p = 0.018). The majority were male (76.7%), and the age 
range was 21 to 98 years. The females were older than the males (52.6 ± 
11.8 vs 56.2 ± 10.7 yrs; t = -3.4, t = 257, p = 0.001). Illness duration ranged 
from 3 to 58 years, and 64.4% had EPSE (SARS ≥ 3). The median duration of 
antipsychotic exposure was 14 years (interquartile range, 8 – 24 years) and 
the current median antipsychotic dose was 336.9 CPZ eq mg/day 
(interquartile range, 125 – 800 mg). Only 6 patients were receiving an atypical 
antipsychotic (risperidone) and they were included into the study. Three 
hundred and ninety-one patients (65%) were prescribed the anticholinergic 
agent trihexyphenidyl, its median daily dose was 4.0 mg (interquartile range, 2 
– 6 mg) and the median duration of anticholinergic exposure was 8.5 years 
(interquartile range, 5 – 15 years). Forty-one percent of the 367 patients who 
were receiving concurrent anticholinergic agent had TD. Forty percent of the 
235 patients without this medication had TD (χ2 = 1.82, p = 0.19).    
The overall prevalence of those meeting the Schooler and Kane criteria 
for TD was 39.3% (CI 35.3 to 43.3%). For the Chinese and Malay patients, 
the prevalences were 40.6% and 29.0% respectively (OR = 0.60, lowered risk 
for the Malays), a difference of 11.6% (CI –0.5% to 23.6%).  
Apart from ethnicity and gender, only potential risk factors that were 
statistically significant (P<0.05) are included in Table 1 which reports the 
univariate logistic regression. As previously noted, the risk of TD amongst the 
Malays was lower (OR = 0.60) but not significant (p = 0.079), while there was 
no sex effect. There were increased risks of TD with age, duration of 
antipsychotic exposure, and SARS scores, while a higher current 
antipsychotic dose was associated with a decreased risk. Examination of the 
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profile of risk effected by increasing SARS scores suggested that the risks in 
each of the groups assigned by band scores of 3 – 5, 6 – 8 and 9 – 29 were 
very similar. As a consequence, only the presence or absence of EPSE (i.e. 
SARS score of 3 or more) was used in the subsequent multivariate analysis. 
  The multiple logistic model (summarised in Table 1) examining the 
role of ethnicity in TD after adjusting for the combined effects of age, duration 
of neuroleptic exposure, current antipsychotic dose and presence of EPSE, 
eliminated both duration of neuroleptic exposure and the presence of EPSE 
from the model due to statistical non-significance. The adjusted estimate of 
the OR for TD in the Malays (compared to Chinese) was then 0.78 (CI 0.42 to 
1.45) which was not significant (p = 0.44). The significant variable associated 
with a greater chance of TD was older age while a high current antipsychotic 
dose (of ≥500 mg CPZ eq) was associated with a decreased chance of TD.   
  
DISCUSSION 
The rates of TD among our schizophrenic patients were 40.5 % and 
29.0 % for the Chinese and Malays respectively. We have excluded those 
who had not be able to give us informed consent including those who could 
but had refused to participate. Unfortunately, we could not gather the relevant 
socio-demographic and clinical data to make a comparison, and hence it 
remains unknown if the rates could have been significantly affected by the 
exclusion of this group. 
In Table 2, we compare our findings with other studies of Chinese 
subjects using similar assessments such as the AIMS (Table 2), identifying 
the highest rate of TD in our sample.  Two earlier studies done in Singapore in 
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the same hospital reported rates of 2.5% (43) and 10% (104) although the 
instruments used were different, as were the diagnostic criteria and the ethnic 
composition of the subjects, and antipsychotic exposure. Interpreting findings 
from different studies is fraught with difficulties, as highlighted by Swartz and 
colleagues (150), reflecting differences in methodologies, medication 
variables (e.g. dose and duration of exposure) and other possible determining 
and confounding variables.  
One explanation for our high prevalence rate may be the relatively 
older age of our patients (mean of 52.8 years) coupled with the long duration 
of antipsychotic use (median of 14 years).  Woerner and associates (85) 
estimated that the rate of TD for patients aged 50 years or more is three to 
five times that of younger age groups. The risk of TD also increases with the 
length of antipsychotic treatment, with one representative prospective study 
(20) demonstrating cumulative incidences of TD as 26% after 1 year, 52% 
after 2 years, and 60% after 3 years of antipsychotic exposure. 
Our patients also had long exposure to anticholinergic medications. 
This may reflect a routine practice of prophylactic anticholinergic medications 
being prescribed together with antipsychotics, or it may also reflect a high 
level of extrapyramidal side-effects which necessitated the addition of this 
medication. The role of anticholinergic drugs in the development of TD 
remains still controversial, although, in a population of 1745 patients, 
Muscettola et al. (37) reported that the combined use of antipsychotic and 
anticholinergic drugs was associated with a significantly increased rate of TD.  
Contrary to other studies (84,85) that indicated an increased risk of TD in 
diabetic patients, we found no association. However, we did not ascertain the 
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prevalence of undetected diabetes among our patients. Despite being older, 
we did not find an increased risk with the female gender. Unfortunately, we 
could not establish the number of female subjects who were postmenopausal, 
as this could have been a contributory factor to our findings: estrogen has 
been suggested to serve a protective role against antipsychotic-induced 
striatal dopamine pathology (150).  
The risk factors that remained significant after both univariate and 
multivariate analyses (other than older age) were the current daily 
antipsychotic dosage and the mean Simpson-Angus Scale score for 
parkinsonism. The association of greater age with TD is in agreement with 
most epidemiological studies (24,143).  The association of a lower current 
dose of antipsychotics with a higher risk of TD has been reported previously 
(42,45). While the cross-sectional design of the study makes it difficult to 
interpret this finding, we postulate that high dose antipsychotic effectively 
“masked” TD. The lower dosage of antipsychotic drug among those with TD 
might alternately be a result of a deliberate dose reduction following the 
development of TD.  
Our patients with TD also had significantly higher scores for 
parkinsonism on the Simpson-Angus Scale. Data on the coexistence of EPS 
and TD are conflicting (151). Several reports have suggested that EPS are a 
risk factor for later developing TD (26,85,115). In addition, increasing age is a 
risk factor for both antipsychotic-induced parkinsonism and TD (28). The 
effect of age and the current antipsychotic dose could account for the 
weakening of the association between EPSE status and TD which was 
significant in the univariate analysis but not with multivariate analysis. 
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Our study has the inherent limitations of a cross-sectional design, and 
we were not able to establish the time of onset of TD, or the dose and length 
of antipsychotic exposure before the development of TD. Due to the pervasive 
use of multiple antipsychotics in this Institute (152), we were also unable to 
elicit if any of the typical antipsychotics presents a differentially smaller risk. 
Whether drug type is important has remained controversial nor is there any 
empirical evidence that depot antipsychotics are more likely to cause TD (9). 
The small number of patients on atypical antipsychotics also did not permit us 
to do any meaningful statistical analysis on their association with TD. We also 
do not know the contribution of spontaneous dyskinesia to the prevalence 
rate, an issue assessed in several studies of well-defined antipsychotic-naïve 
schizophrenic patients with prevalence rates varying from 0% to 5% (24, 26); 
nor the presence of edentulism which may be associated with TD (124,125). 
Even taking these issues into consideration, the rate of TD among our 
Chinese patients with schizophrenia would remain the highest compared to 
other studies based on homogeneous Chinese populations. Such a high rate, 
and comparable to the highest rates in western populations, suggests that any 
variation in prevalence among Chinese in different settings is likely to be due 
to parochial factors such as prescribing patterns rather than due to genetic or 
ethnicity factors.  
Turning to our study focus, univariate analyses suggested a distinct 
trend for a higher rate of TD in Chinese than in Malay patients (p = 0.08). 
However, this trend was attentuated and was non-significant when, in the 
multivariate analysis, we controlled for other risk variables, suggesting that the 
base rate difference was due to factors such as age, duration and current 
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dose of neuroleptic drugs. Tempering this though, was the relatively small 
sample size of the Malays with the possibility that a type 2 error might have 
been committed.  
Thus, our findings do not suggest that intraethnic differences are likely 
to exist between Chinese, Malays and Western subjects in the vulnerability for 
developing TD, and indicates that it is unlikely that varying TD prevalence 
rates reflect varying vulnerability across ethnic groups although this would 
have to be further verified across other ethnic groups. 
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Table 1.  Examination of influence of risk factors on prevalence of TD, examined in both univariate and multivariate 
analyses 
 
     Univariate analysis  Multivariable analysis 
  N %  OR 95% CI P  OR 95% CI P 
            
Race Malay 65 10.8  1.0         1.0   
 Chinese 537 89.2   1.65 0.94 – 2.90 0.079  1.25 0.67 – 2.34 0.47 










0.90 – 1.94 
 
0.16 
    
            
Age (yrs) ≤39 76 12.6  1.0    1.0   
 40-49 161 26.7       1.58 0.75 – 3.32   1.56 0.68 - 3.31  
 50-59 196 32.6    5.01 2.50 – 10.08    4.04 1.87 – 8.72   
 60-69 126 20.9    9.28 4.46 – 19.31   6.31  2.74- 14.54  
 ≥70 43 7.1    8.20 3.40 – 19.79 <0.0001  4.73 1.78 – 12.58 <0.0001 
            













  1.43 
  2.08 
 
0.78 – 2.65 









0.66 - 2.65 


















  0.59 
  0.12 
 
0.23 – 1..53 








0.25 - 1.94 




            
SARS score 0-2 222 36.9  1.0       
 3-5 143 23.8   1.77 1.14-2.74      
 6-8 84 14.0   1.82 1.09-3.06      
 9-29 153 25.4   2.00 1.31-3.07 0.006     
            
EPSE Absent 222 36.9  1.0    1.0   
 Present 380 63.1   1.87 1.32 – 2.66 0.0005  1.45 0.98 – 2.14 0.065 
            
Diabetes Absent 237 95.2  1.1 0.52-2.5 0.43     
 Present 12 4.8  0.99       
OR odds ratio; OR < 1.0 indicates decreased risk and OR > 1 indicates increased risk in relation to a reference variable given a score of 1.0 for each risk factor; 
95% CI = 95% confidence interval; TD = tardive dyskinesia; SARS = Simpson-Angus Rating Scale; EPSE = extrapyramidal side effects. 
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Pi et al (7) Beijing 232 42 95 580 18 - 74 8 
 Yanji  70 40 97 354 16 - 36 17 












































Aim: The role of impaired glucose metabolism in the pathophysiology of 
tardive dyskinesia (TD) in patients of schizophrenia with and without 
persistent TD is examined.   
Method: Glucose tolerance and insulin levels were determined in 86 patients 
with persistent TD and 108 patients without TD. Dyskinesias were assessed 
by the Abnormal Involuntary Movement Scale (AIMS) and extrapyramidal 
symptoms by the Simpson–Angus Rating Scale (SARS).  
Results: Fasting blood glucose levels were significantly lower while the first 
and second hour glucose levels did not reveal any differences in patients with 
TD as compared to those without TD. Insulin levels did not differ in these two 
groups.  
Conclusion: Our cross-sectional epidemiological study does not suggest 
hyperglycemia to be a risk factor for TD. However, prospective long-term 
studies with multiple assessment points are needed to clarify the role of 









The pathophysiology of tardive dyskinesia (TD) is yet to be elucidated 
and is likely to involve the complex interactions of various factors. Proposed 
hypotheses include interactions with drug-induced changes in the receptors in 
the stratium and age-related degenerative changes in the nigrostriatal system 
(144). Older patients are also more likely to develop diabetes mellitus and 
cerebrovascular insults which may in part account for the increased 
vulnerability for TD (153).  
There is some evidence that diabetes increases the risk of both 
spontaneous dyskinetic movements and TD (84,85).  Fasting blood glucose 
has also been observed to be higher among those with tardive dyskinesia (86, 
154)  
The pathophysiology of this association between hyperglycemia and 
TD is unknown. Glucose induced dopamine sensitivity has been suggested in 
animal studies (155) and a possible genetic factor may also be involved as 
suggested by a report (89) which found greater incidence of diabetes in 
relatives of patients with TD. 
In this study, the role of glucose metabolism in the pathophysiology of 
TD was examined in schizophrenic patients with and without TD. 
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METHOD 
The subjects were recruited from the pool of 602 patients who 
participated in the initial epidemiological survey. Informed written consent was 
obtained after the nature of this particular study had been fully explained.  
Patients were given an oral glucose tolerance test after an overnight 
fast. Fasting glucose and insulin levels were obtained at the start of the 
testing period. Serum glucose levels were determined using enzymatic 
method, and insulin concentration was determined using Microparticle 
Enzyme Immunoassay. We defined impaired glucose tolerance as a fasting 
glucose level of ≥ 140mg/dl and 2-hr glucose levels of ≥ 150mg/dl.  
All analyses were carried out using SPSS (version 8.0). Normality of 
data was checked using the Kolmogorov Smirnov 1-Sample test. Differences 
in baselines between the patients with TD and without TD were determined 
using 2-Sample t-test when normality assumptions were satisfied; otherwise 
Mann-Whitney U test was used. Association between glucose levels and 
movement ratings were established using partial correlations. Correlations 
were established to fasting, 1-hour and 2-hour glucose levels while controlling 
for age, sex and daily antipsychotic dose. We also used partial correlation to 
associate insulin resistance with abnormal movements, controlling for glucose 
measures.   
 
RESULTS 
Of the 194 patients in the study, 182 were Chinese and 12 were 
Malays. Eighty-six (44.3%) had persistent TD (71 males; 15 females) while 
108 patients did not have TD (55.7%) (84 males; 24 females). None of the 
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patients had received any atypical antipsychotics either in the past or at the 
time of the study. The description of these two groups is presented in Table 1.  
Both groups were comparable except for the current antipsychotic 
dosage and the fasting glucose level. The group with TD had a significantly 
lower daily dose of antipsychotic and fasting glucose level (p < 0.001 and p = 
0.004, respectively, Mann Whitney U-test). The same predictors were 
significant when a stepwise logistic regression was carried out. A significant 
negative correlation was observed between the AIMS score and the glucose 
measures at fasting, 1-hour and 2-hour interval, when we controlled for age, 
sex and daily antipsychotic dose in CPZ equivalents (r = -0.18, p = 0.01; r = -
0.17, p = 0.02, r = -0.16 and p = 0.03 respectively). No significant correlation 




Our findings were contrary to the findings of Mukherjee and coworkers 
(156) who reported higher fasting blood glucose in TD patients and Schultz et 
al. (154) who reported a significant correlation between AIMS score and 
baseline blood glucose.  Both these studies however, did not control for 
antipsychotic dose. Antipsychotics have been reported to induce 
hyperglycemia (157,158) and increase fasting blood glucose. In addition, 
patients with TD were demonstrated to have abnormal fasting glucose levels 
while on antipsychotics that normalised in the antipsychotic free state. It is 
possible that the effect on blood glucose as exerted by antipsychotics follows 
a dose or concentration dependent pattern. Our patients without TD were 
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receiving a higher current dose of antipsychotics which may explain the 
negative association between TD and fasting blood glucose levels in our 
patients. Although the higher dose of antipsychotics could have led to 
masking of dyskinetic movements from antipsychotic-induced 
pseudoparkinsonsim, this did not seemed likely as the mean Simpson-Angus 
score did not significantly differ from those with and without TD. However, the 
lower antipsychotic dose in our TD patients could have been reduced 
subsequent to the diagnosis of TD. Other than dosage, the types of 
antipsychotics may also be important. Although all our patients were on 
typical antipsychotics and phenothiazines have been reported to cause 
glucoregulatory abnormalities (159,160), this association has not been 
reported for all typical antipsychotics (161). Due to the pervasive practice of 
polypharmacy in this population (152), we could not examine the possible 
differential effect that the various classes of typical neuroleptics have on 
glucose regulation. Unlike the findings of Schultz et al. (154), we found no 
elevation in the insulin levels; which is consistent with the reports that typical 
antipsychotics do not elevate insulin levels (158).    
Our cross-sectional epidemiological study does not suggest 
hyperglycemia to be a risk factor for TD. However, prospective long-term 
studies with multiple assessment points are needed to clarify the role of 




    
 
Table 1.  Demographic and clinical characteristics of patients with and 

















Age of onset of illness 
(years) 22.5 (7.6) 22.7 (6.9) 
Cumulative exposure to 
antipsychotics (years) 19.0 (10.4) 19.4 (10.9) 
Daily dose of diazepam  
(mg/day) 2.0 (3.7) 2.3 (4.1) 
Daily antipsychotic 
dose(mg/day)* 266.9 (243.5) 614.8 (602.6) 
Simpson-Angus Rating Scale 
(mean score) 6.3 (6.3) 5.7 (6.3) 
GTT  Fasting (mg/dl)* 91.0 (16.0) 103.0 (38.6) 
GTT 1 hr(mg/dl) 185.3 (56.2) 193.6(74.3) 
GTT 2 hrs (mg/dl) 144.6 (61.7) 161.8 (86.1) 
Insulin Fasting (mU/l) 4.4 (3.5) 5.0 (3.6) 
 
































Aim: Iron has been implicated in the pathophysiology of tardive dyskinesia 
(TD) through its role in the production of free radicals. This study sought to 
establish the association between the blood indices of patients with 
schizophrenia and TD. 
Method: One hundred and ninety-four patients who fulfilled DSM-IV criteria 
for schizophrenia were assessed with the Abnormal Involuntary Movement 
Scale (AIMS) and the Simpson-Angus Rating Scale. A single sample of 
venous blood was drawn in the morning for measuring iron indices i.e. serum 
iron, ferritin and total iron binding capacity (TIBC) were drawn in the morning.  
Results: We found no association between peripheral iron indices and TD. 
The group without TD were receiving a significantly higher daily dose of 
antipsychotics. 
Conclusion: While the findings seem to refute the role of iron in TD, the 
caveats were the suspected accuracy of peripheral blood iron indices as an 





One of the hypotheses of TD posits that it is a consequence of free radicals 
damage. Iron catalyses the formation of free radicals, which can result in 
neurotoxicity, particularly in the basal ganglia where both iron and dopamine 
levels are high (162). Wirshing et al. (118) reported a positive correlation 
between the Abnormal Involuntary Movement Scale and serum ferritin. In this 
study, we sought to establish if there was any association with TD and 
peripheral iron indices.  
 
METHOD 
The patients were recruited from pool of 602 patients and as they were all 
long-stay inpatients, they received a similar diet and share a similar lifestyle. 
One hundred and ninety-four patients consented to participate in the study.  
A single sample of venous blood was drawn in the morning for 
measuring iron indices i.e. serum iron, ferritin and total iron binding capacity 
(TIBC) were drawn in the morning. Serum iron was measured by a 
colorimetric method (reference range of the 11-29 umoles/litre, coefficient of 
variation = 4%). Ferritin was measured by a microparticle enzyme 
immunoassay (reference range of the laboratory being 32-294 ugms/litre, 
coefficient of variation = 7%). 
All analyses were carried out using SPSS (version 8.0). Normality of 
data was checked using the Kolmogorov Smirnov 1-Sample test. Differences 
in baselines between the patients with TD and without TD were determined 
using the 2-Sample t-test when normality assumptions were satisfied; 
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otherwise the Mann Whitney U-test was used. Statistical significance was 
achieved with p < 0.05. 
 
RESULTS 
Of the 194 patients in the study, 182 were Chinese and 12 were 
Malays. Eighty-six (44.3%, 95% CI 36.8% to 51.8%) had persistent TD. The 
description of these two groups is presented in Table 1.  
A stepwise logistic regression was performed using presence of TD as 
the dependent variable and age, gender, cumulative exposure to 
antipsychotics, daily dose of diazepam, daily dose of antipsychotics, SARS 
score and iron indices as the covariates. The final model was adjusted for 
multi-colinearity. Both groups were comparable except for the current 
antipsychotic dosage (p < 0.001, Mann Whitney U-test), which remained 
significant when a stepwise logistic regression was carried out. There was no 
significant difference of the iron indices between the two groups.  
 
DISCUSSION 
Our study found that patients with TD were receiving a lower dose of 
antipsychotics.  While the cross-sectional design of the study makes it difficult 
to interpret this finding, we postulate that the lower dosage of antipsychotics 
among those with TD might alternately be a result of a deliberate dose 
reduction following the development of TD.  While a higher dose may “mask” 
TD, it did not seem to be the case among our patients as the mean Simpson-
Angus Scale scores between the two groups did not differ. 
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Iron is essential for the production of hydroxyl radicals which is the 
most damaging of all free radicals. It is possible that antipsychotics interact 
with the iron in the basal ganglia leading to higher levels of hydroxyl radicals 
and accelerated neuronal degeneration. Wirshing et al. (118) also suggested 
an alternative mechanism through arteriosclerotic disease which itself is 
associated with increased peripheral ferritin levels and may predispose to the 
development of TD. 
However, we did not find an association with TD and peripheral iron 
indices, in keeping with the findings of Sachdev (162). Serum iron indices may 
also not be an accurate reflection of brain iron due to the protective effect of 
an intact BBB; furthermore, antipsychotics may be able to mobilize the 
peripheral iron stores to the brain or decrease iron turnover in the brain 
without any significant changes in the serum iron indices (163). The role of 
ethnic differences remained to be examined although our initial 
epidemiological survey suggested that the risk for TD among the Chinese and 
Malays does not appear to be less than among Westerners.  
Our cross-sectional epidemiological study does not suggest a link 
between peripheral iron and TD. Prospective long-term studies with multiple 
assessment points and serial brain imaging for iron deposition are needed to 























Gender (M/F) 71/ 15 84 / 24 
Age of onset of illness 
(years) 22.13 (0.86) 22.38 (0.74) 
Cumulative exposure to 
antipsychotics (years) 19.66 (1.27) 19.83 (1.13) 
Daily dose of diazepam  
(mg/day) 1.93 (0.46) 2.47 (0.46) 
*Daily antipsychotic dose 
(mg/day) 276.21 (31.27) 672.87 (69.55) 
Simpson-Angus Rating Scale 
(mean score) 6.43 (0.71) 6.59 (0.72) 
Ferritin (ugrams/litre) 113.62 (10.81) 129.13 (12.45) 
Iron (umol/litre) 15.72 (0.71) 15.13 (0.64) 
**TIBC (umol/litre) 
50.52  (1.46) 51.87 (0.55) 
 










POLYMORPHISMS OF DOPAMINE RECEPTORS AND TARDIVE 























Aim: The putative role of dopamine in the pathophysiology of TD makes the 
genes coding for dopamine receptors the appropriate candidate genes to be 
studied. This study investigates the association of the polymorphism of the 
Ser311Cys and Ser9Gly of the dopamine D2 (DRD2) and D3 receptor (DRD3) 
genes respectively with TD in Chinese patients with schizophrenia.  
Method: In a case-control study, 117 Chinese patients with TD were 
compared with 200 patients without TD. They were diagnosed to have 
schizophrenia according to DSM-IV criteria. Dyskinesia was assessed by the 
Abnormal Involuntary Movement Scale (AIMS), while extrapyramidal side-
effects (EPSE) were assessed by the Simpson-Angus Rating Scale. 
Results: Genotype groups were comparable in age, gender, duration of 
illness, daily antipsychotic and benzodiazepine dose as well as the mean 
scores for EPSE. We failed to find an association between the polymorphism 
of the DRD2 gene with TD but found an increased risk of developing TD 
among those with D3 serine/serine genotype. 
Conclusions: Our results did not indicate that the D2 genotype has a role in 
the pathophysiology of TD in Chinese patients with schizophrenia. The 
association of TD with the serine/serine genotype of the DRD3 may be an 
epiphenomenon of patients with a subtype of schizophrenia who had more 






The predominant hypothesis of TD postulates that it results from 
chronic antipsychotic blockade of dopamine receptors in the basal ganglia 
which results in an upregulation of dopamine receptors on postsynaptic 
membranes (164). However, as not all patients treated with antipsychotics 
develop TD, there is a variable susceptibility to the disorder. Part of this 
variability may be due to genetic factors (73,165,166). The putative role of 
dopamine in the pathophysiology of TD makes the genes coding for the 
dopamine receptors the appropriate candidate genes to be studied.  
This study investigates the association of the polymorphism of the 
Ser11Cys and Ser9Gly of the dopamine D2 (DRD2) and D3 receptor (DRD3) 
gene respectively with TD in Chinese patients with schizophrenia. These 2 
polymorphisms were chosen as there was no study done among Chinese for 
the former polymorphism, while 2 previous studies on Chinese subjects 
yielded conflicting findings (167,168).  
 
METHOD 
All subjects were diagnosed to have schizophrenia according to DSM-
IV criteria and who were recruited from the 602 patients who were surveyed. 
Written informed consent was taken separately for this study/ 
Genetic Analysis 
Genomic DNA was extracted from blood using QIAamp Blood Kit 
(QIAGEN GmbH, Germany). Genotyping of both polymorphisms was done by 
PCR-RFLP. Primers and conditions for the DRD2 Ser11Cys polymorphism 




polymorphism, according to Basile et al. (170). The genotyping was 
performed blind to the clinical status of the patients.  
Statistical Analysis  
Differences in the patient’s demographic characteristics, current 
antipsychotic dose, AIMS score and SARS amongst the different genotypes 
were determined using the Kruskal-Wallis test. Associations in genotypic and 
allelic distribution between patients with TD and those without TD were 
analysed using the chi-square test. A chi-square analysis was also used to 
test whether the distribution of genotypes was in accordance with the Hardy-
Weinberg equilibrium. A logistic regression analysis was performed using TD 
as the dependent variable and age, gender, duration of illness, antipsychotic 
dose, DRD2 and DRD3 genotypes as the covariates. 
RESULTS 
The chi-square test found the distribution of the genotypes to be in 
accordance with the Hardy-Weinberg equilibrium. Table 1 shows the 
demographic and clinical features of patients in the three genotype groups. 
There was no significant difference in age, gender, duration of illness, 
cumulative duration of antipsychotic use and daily antipsychotic dose. As 
benzodiazepine use may suppress TD (12), we determined the proportion of 
patients in each genotypic groups who were receiving benzodiazepines and 
found no significant difference (Ser311Cys: χ2  = 3.53, df = 2, p = 0.17; 
Ser9Gly: χ2  = 3.94, df = 2, p = 0.14). The presence of parkinsonism may also 
mask dyskinetic movements but in our study we found no significant 
difference in the mean SARS score amongst the genotypes (Ser311Cys: χ2 = 




ersistent TD did not differ significantly for Ser311Cys (χ2  = 1.76, df = 2, p = 
0.43) or Ser9Gly (χ2  = 1.44, df = 2, p = 0.50) genotype groups. There was 
also no significant difference observed in the total AIMS score among the 
genotype groups (Ser311Cys: Kruskal-Wallis test, p = 0.25; Ser9Gly: Kruskal-
Wallis test, p = 0.85). Patients with TD and those without TD did not differ 
significantly in the distribution of allele frequencies (Ser311Cys: χ2 = 1.86, p = 
0.17; Ser9Gly: χ2 = 1.34, p = 0.24). 
After adjusting for the confounding variables by logistic regression we 
found significant association of TD with age (p<0.005) and the serine-serine 
genotype (p=0.012) of the DRD3 gene. 
 
DISCUSSION 
To date, there has been only one report of a positive association 
between TD and the dopamine D2 receptor TaqI A polymorphism (74), results 
from all other studies were negative. In this study with patients from the same 
ethnic group as that used in the original study with the positive finding, we did 
not find an association with the Ser311Cys polymorphism. Investigations of 
three other polymorphisms in the DRD2 gene also did not turn up any positive 
association (171).  
The DRD3 gene has been more extensively studied as a candidate 
gene for TD. The Ser9Gly polymorphism has been implicated in a number of 
reports. Steen et al. (77) reported an association with the glycine/glycine 
genotype and Segman et al. (172) reported an excess of the glycine-
containing genotypes in patients with TD. Basile et al. (170) had reported a 
significantly higher mean AIMS scores for those with glycine/glycine 
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genotype. There were also two studies which reported negative association 
for this polymorphism (173,174). 
Two studies have examined this polymorphism and its possible 
association with TD in Chinese subjects. Garcia-Barcelo et al. (167) found no 
association while the second study found higher mean AIMS scores in 
heterozygous patients (168). The frequency of the DRD3-glycine allele among 
our patients (26%) is similar to those reported for other Chinese patients (167, 
168) which is lower than Caucasians (77,172-174). The relatively few DRD3 
gly-gly homozygotes with reduced statistical power may make it difficult to 
demonstrate an effect for TD. There may also be ethnic differences in the 
phenotypic expression for the glycine/glycine genotype as suggested by 
report of an association with this genotype with schizophrenia in Causasian 
subjects (174) while none was found among Asian subjects (175-179).  
Most of the studies on DRD3 polymorphism (77,172-174) have 
considered the daily dose of medication, only one study (172) had included 
the duration of treatment. However, none of the studies (77,172-179) had 
estimated the cumulative antipsychotic exposure, which is postulated to be a 
risk factor for TD. The number of patients in our study provides a power of 
83% with a 5% significance level to detect an odds ratio of 2 for the 
serine/serine genotype for TD. The serine/serine genotype has been linked to 
nonresponsiveness to clozapine (180). It is thus possible that this 
polymorphism is related to certain subtypes of schizophrenia i.e. treatment-
resistant schizophrenia (181). These patients are likely to be prescribed 
higher doses of antipsychotics during the course of their illness in the effort to 




TD (36,182). Hence, the increased risk of TD among those with the 
serine/serine genotype may be an epiphenomenon rather than a direct 
relationship. However, we did not establish if these patients with the 
serine/serine genotype had indeed fulfilled the criteria of being treatment-
resistant. Another explanation for our findings could be that this polymorphism 
is in linkage disequilibrium with the direct causative allele which has yet to be 
identified. As our study was done among Chinese patients, our contrasting 
report may also be due to ethnic differences. It is possible that while the Ser9 
allele is associated with TD in Chinese, a different allele may be linked to TD 
in another ethnic group.  
While our finding do not suggest that the polymorphism of the 
Ser11Cys of DRD2 gene and Ser9Gly of DRD3 gene are directly involved in 
the pathogenesis of TD, a genetic vulnerability is probably involved. It is likely 
that other factors are important - one of which is the cumulative exposure to 
antipsychotics. Therefore any study investigating the genetics of TD should 





















(CPZ eq: mg/day) 
Daily dose of 
diazepam 
(mgs) 
AIMS Score SARS 
Ser311Cys         
Genotype Ser/Ser 47/16 52.1 ±10.3 29.4±10.5 524.8±551.0 2.5±4.2 1.91±2.74 6.22±6.08 
 Ser/Cys 108/34 53.0±11.8 27.9±9.7 577.6±607.9 1.7±3.4 2.33±2.89 5.70±5.84 
 Cys/Cys 77/35 54.8±10.7 30.4±8.8 595.3±596.5 1.4±3.3 2.66±3.46 6.51±6.75 
TaqI A         
Genotype Ser/Ser 113/38 54.3±11.8 29.4±9.4 576.3±595.0 1.7±3.5 2.56±0.43 6.12±6.20 
 Ser/Gly 96/37 53.0.±11.0 28.8±9.9 567.6±589.7 2.1±3.8 2.22±2.94 6.15±6.56 
 Gly/Gly 23/10 52.0±8.8 29.1±9.2 586.5±604.7 0.8±2.5 2.16±2.56 5.71±4.85 
 






Table 2.  Genotypes and allele frequencies of DRD2 and DRD3 in patients with and without TD 
 








Genotype Ser/Ser 19 42 
 Ser/Cys 52 92 
 Cys/Cys 46 66 
 
 
Allele frequency Ser 0.38 0.44 
 Cys 0.62 0.56 
Ser9Gly    
Genotype Ser/Ser 60 89 
 Ser/Gly 46 88 
 Gly/Gly 11 23 
Allele frequency Ser 0.71 0.66 















SUSCEPTIBILITY TO ANTIPSYCHOTIC-INDUCED TARDIVE DYSKINESIA 


















Aim:  In this study, we examined the association of the T102 polymorphism in 
the 5-HT2A receptor gene as a risk factor for developing schizophrenia and 
tardive dyskinesia from prolonged treatment with antipsychotics.  
Method: Ninety-seven healthy controls with no history of mental illness and 
221 schizophrenic patients (87 with TD, 134 without) were genotyped by 
PCR-RFLP.  
Results: Comparison between cases and controls revealed no significant 
association between the C allele and schizophrenia. There was a significant 
difference in allele frequency (p=0.044, OR=1.54 95% CI=1.02-2.33) between 
patients who developed TD and those who did not. Significant difference 
remains even after adjusting for age and antipsychotic dosage (p=0.041) with 
the odds ratio at 1.64 (95% CI=1.02-2.62).  
Conclusion: The T102C polymorphism may be useful in predicting 
susceptibility to antipsychotic-induced TD in schizophrenia. 
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INTRODUCTION 
Antipsychotic treatment may result in the development of tardive 
dyskinesia (TD), the pathophysiology of which has yet to be elucidated. 
Supersensitivity of the striatal dopamine system from the chronic use of 
dopamine antagonists such as the typical antipsychotics has been postulated 
to be involved in TD (183). Other than dopamine, serotonin may also be 
involved.  The typical antipsychotics also have varying serotonergic 
interactions, varying from negligible (e.g. haloperidol) to moderate (e.g. 
chlorpromazine). The activity of the nigrostratial dopaminergic neurons is 
tonically inhibited by serotonergic projections from the dorsal raphe (184). 
Selective serotonin reuptake inhibitors (SSRIs) which have been reported to 
cause TD (185,186) could act via these connections in reducing the release of 
synaptic dopamine in the nigrostriatal system. Chronic decreases in 
dopaminergic transmission may in turn facilitate hypersensitivity of the 
postsynaptic dopamine receptors thereby giving rise to TD.  
In this study, we examine the association of a polymorphism in the 5-
HT2A receptor gene as a risk factor for developing tardive dyskinesia from 
prolonged treatment with antipsychotics. Our sample consists of 97 controls, 
87 schizophrenic patients with TD and 134 patients without TD. 
 
METHOD 
Patients for this study were recruited from Woodbridge Hospital. Only Chinese 
patients who consented to participated were recruited from the population 
who were participated in the epidemiological survey on TD. Controls are 
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ethnically-matched volunteers with no history of mental illness.  Written 
informed consent was taken. 
Genetic analysis 
Venous blood was collected in EDTA tubes and genomic DNA was extracted 
with QIAamp Blood Kit (Qiagen GmbH, Hilden, Germany). The region of 
interest was amplified by polymerase chain reaction. Sequence of the forward 
primer was 5’-TCTGCTACACCGTTCTGGCTT-3’ while sequence of the 
reverse primer was 5’-CTGCAGTTTTTCTCTAGGG-3’. PCR was carried out 
in a volume of 10 μl consisting of genomic DNA, 2 mM of each of the 4 
deoxyribonucleotides, 5 pmole of each primer, 10 mM Tris-HCl pH 8.3, 50mM 
KCl, 1.5 mM MgCl2 and 1 unit Taq polymerase (Boehringer Mannheim 
GmbH, Germany). Cycling conditions are: an initial denaturation at 94°C for 5 
minutes, 30 cycles of denaturation at 94°C for 20 seconds, annealing at 60°C 
for 20 seconds, and extension at 72°C for 20 seconds, followed by a final 
incubation at 72°C for 10 minutes. PCR products were incubated with the 
restriction enzyme MspI according to manufacturer’s instructions (New 
England Biolabs, USA) prior to electrophoresis on a 2% agarose gel. 
Resulting products were detected by ethidium bromide staining. Amplicons 
corresponding to the T allele would be left intact while those with the C alleles 
would be cleaved into 2 bands. 
Statistical analysis 
Differences in allele and genotype frequencies between groups were 
assessed with either univariate or multivariate analysis. In univariate analysis, 
the difference between groups of patients with respect to genotypes and allele 
frequencies was compared using the chi-square test and the two-tailed Fisher 
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exact test. In multivariate analysis, multivariate logistic regression models 
were used to adjust for the effect of age and CPZ. Only univariate analyses 
were done for comparisons relating to the control group.  
The chi-square test was used to check whether the distribution of 
genotypes was in accordance with Hardy-Weinberg equilibrium. Probability 
values of 0.05 or less were regarded as statistically significant.   
 
RESULTS 
The study group comprised 221 patients who met DSM-IV criteria for 
schizophrenia, in addition there were 97 normal control subjects 
(Male/Female =64/33). The demographic and clinical data for the patients are 
summarized in Table 1. 
Comparison between  patients with schizophrenia and controls 
The distribution and frequency of the genotypes are shown in Table II. 
There was significant difference in the distribution of the three genotypes for 
the healthy controls, schizophrenic patients with TD and non-TD 
schizophrenic patients (χ2 = 18.815, df = 4, p = 0.001). When the last two 
groups were combined as one, there was an excess of the T-containing 
genotypes (T/T and T/C) in the schizophrenic group compared to the controls 
(χ2 = 6.47, df = 2, p = 0.039). However, there was no significant difference in 
the allele frequencies between the control and schizophrenic group (χ2 = 





            
 
 
Comparison between schizophrenic patients with TD and without TD  
There was no significant difference in the male/female ratio between the TD 
and non-TD groups (p = 0.539). However, age and antipsychotic dosage were 
significant variables which have to be adjusted for in subsequent analysis. 
Compared to patients who developed TD, there was an excess of the T/T 
genotype in the non-TD group (χ2  = 6.517, df = 2, p = 0.038). There was also 
significant difference in allele frequencies between the two groups (χ2  = 
4.189, df = 1, p = 0.044) with the odds ratio of 1.54 (95% CI=1.02-2.33). For 
genotype distribution, the significance level is lower (p = 0.055) after adjusting 
for the two significant variables, age and daily antipsychotic dose in CPZ eq. 
Significant difference in allele frequency remains even after adjusting for age 




Several independent lines of evidence implicate serotonin in the 
pathogenesis of schizophrenia (187,188). Genes involved in the 
serotoninergic transmission pathway are thus potential candidate genes for 
schizophrenia.  
The T102C polymorphism in the 5-HT type 2A receptor gene is a silent 
mutation first identified by Warren et al. (189) Association of the allele 2 
(102C) with schizophrenia have been reported (190-193). Negative findings 
have also been reported for Irish (194), Japanese (195,196), Italians (197), 
British and Chinese (198,199).  
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The odds ratio of 1.64 with a p value of 0.041 might be due to relatively 
small sample size. One strategy is to do pooled analysis from different studies 
although population stratification would be confounder if these studies were 
conducted among different ethnic populations. 
One such large multi-centre study of 571 patients with schizophrenia 
and 639 controls upheld the significant association with allele 2 or the C allele 
(200). Our results did not reveal any association of schizophrenia with the C 
allele. Instead we found an excess of the T-containing genotypes (T/T and 
T/C) for patients with schizophrenia although there is no difference at the 
allelic level. An earlier Singapore study with Chinese males reported a higher 
frequency of the T allele among schizophrenic patients (201). Interestingly, 
the T102C polymorphism in this gene has been linked to responsiveness to 
clozapine (202).  
Despite several negative reports (203-206), the T102 allele was 
identified among several polymorphisms of the serotonin gene system as 
having the strongest association with good response to clozapine (207). It is 
thus likely that this polymorphism is related to only certain subtypes of 
schizophrenia, such as the treatment-resistant subtype (208). This may partly 
explain why we also found an association with increased risk for antipsychotic 
induced-TD. Patients who are poor responders are likely to be prescribed 
higher doses of neuroleptics in the effort to control the symptoms. 
Longitudinal studies have also provided empirical support that higher dose 
increase the risk of TD (36,38). TD has been correlated positively with both 
total treatment duration and total drug dose (6,11). Taking the dose and 
duration of use together, the total antipsychotic load is considered to be a risk 
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factor.  On the other hand, the 5-HT2A receptor may be involved in the 
primary etiological mechanism of TD. As a silent variant of the 5-HT2A 
receptor gene, the T102C polymorphism may be in linkage disequilibrium with 
some other relevant polymorphisms in another segment of the gene, one of 
which is the promoter polymorphism –1438A/G (192), or another gene in the 
same region of the locus. 
The C allele or allele 2 has been reported to be associated with 
susceptibility to schizophrenia and non-responsiveness to clozapine. Our 
results showed that it might also be associated with increased risk for 
antipsychotic induced-TD. This polymorphism might thus be a useful marker 
to screen for patients who might be at higher risk of developing TD. 
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Table 2.  Comparison of T102C genotype and allele frequencies among the three groups 
 
  Genotype frequency Allele frequency 
 n T/T T/C C/C  T C 
Controls 97 43 (44.3%) 43 (44.3%) 11 (11.3%)  129 (66.5%) 65 (33.5%) 
Schizophrenia (TD) 87 29 (33.3%) 54 (62.1%) 4 (4.6%)  112 (64.4%) 62 (35.6%) 





            
 











SEROTONIN TRANSPORTER GENE POLYMORPHISM 

























Aim: The serotonin transporter participates in the reuptake and termination of 
serotonin neurotransmission and the gene that codes for this protein is thus a 
candidate gene for the development of TD. There is a functional 
polymorphism in the transcriptional control region of the serotonin transporter 
gene and this study investigates the association between this polymorphism 
and TD in Chinese schizophrenic patients.  
Method: In a case-control association study, 81 patients with TD were 
compared with 107 patients without TD. Genotyping were done with PCR-
RFLP.  
Results: The patients who did not differ in age and sex distribution did not 
show variation on the rates of TD and Abnormal Involuntary Movements Scale 
(AIMS) scores with genotypes.  
Conclusion: Our findings suggest that 5-HTTLPR polymorphism is not a risk 
factor for TD in Chinese. 
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INTRODUCTION 
Supersensitivity of the striatal dopamine system from the chronic use of 
the dopamine antagonists such as the antipsychotics has been postulated to 
be involved in TD (183). As the activity of the nigrostratial dopaminergic 
neurons is tonically inhibited by serotonergic projections from the dorsal raphe 
(184), serotonin may also be involved in the pathophysiology of TD. An 
insertion/deletion polymorphism has been reported in the promoter region (5-
HTTLPR) (209). The polymorphism consists of two allelic forms and is 
associated with different 5-HTT promoter activity. The allele designated ‘l’ has 
greater transcriptional activity and subsequently more serotonin reuptake than 
the short allele ‘s’ which is associated with a more restricted transcriptional 
activity of the promoter leading to lower functional expression of the 5-HTT 
(209).  
This study set out to establish if there was an association between TD 
and the 5-HTTLPR polymorphism in 188 Chinese patients with schizophrenia.  
 
METHOD  
Patients for this study were recruited from the 602 patients who initially 
participated in the epidemiological survey on TD. Only patients of Chinese 
descent were approached for the study, and written informed consent was 
obtained from those who agreed.  
Genetic Analysis  
Genomic DNA was extracted from blood using QIAamp Blood Kit 
(QIAGEN GmbH, Germany). The region of interest was amplified with primers 
5'-ATGCCAGCACCTAACCCCTAATG-3' and 5'-AGGGACTGAGCTGGACAA 
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CCCAC-3'. PCR amplification was carried out in a final volume of 10 μl 
consisting of 50ng genomic DNA, 2 mM deoxyribonucleotides containing 7-
deaza-2'-dGTP, 5 pmole of each primer, 10 mM Tris-HCl (pH 8.3), 50 mM 
KCl, 1.5 mM MgCl2 and 1 unit of Taq polymerase (Boehringer Mannheim 
GmbH, Germany). Cycling conditions are: 95°C for 5 minutes, 35 cycles of 
denaturation at 94°C for 30 seconds, annealing at 60°C for 50 seconds and 
synthesis at 72°C for 50 seconds, followed by a final extension step at 72°C 
for 10 minutes. PCR products were detected by ethidium bromide staining 
following electrophoresis on a 2% NuSieve agarose gel. 
Statistical Analysis 
Conformation to Hardy-Weinberg equilibrium for each individual 
population was estimated by the χ2 test. Group differences were tested by the 




The 188 patients comprised 149 (79 %) men and 39 (21%) women. 
The mean ± SD age was 51.8 ± 9.75 years, range 24 – 73 and they were 
receiving a mean ± SD CPZ eq of 598.7 ± 638.7 mg/day, range 50 – 2775. 
None of the patients had received atypical antipsychotic in the past or at the 
time of this study. Upon testing for Hardy-Weinberg equilibrium, we found that 
the genotype frequencies in our sample did not deviate significantly from the 
frequencies expected under random mating condition (χ2 =1.60, df=1, 
p=0.44).  
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Table 1 shows the distribution of the frequency of the three genotypes. 
The three genotypic groups do not differ significantly in the variables which 
are possible risk factors for TD: sex (χ2 = 0.57, df=2, p = 0.75), Kruskal-Wallis 
test results for age (χ2 = 3.5, df=2, p = 0.17), daily antipsychotic dose (χ2 = 
3.3, df=2, p = 0.19) and cumulative duration of antipsychotic use (χ2 = 1.78, 
df=2, p = 0.41). The scores for the Simpson-Angus Rating Scale [Kruskal-
Wallis test, (χ2 =2.80, df=2, p=0.25)] and the AIMS scores also did not differ 
significantly [Kruskal-Wallis test, (χ2 = 0.88, df=2, p=0.64)] among the three 
genotypes. As benzodiazepines may suppress TD (22), we determined the 
proportion of patients in each genotypic groups who were receiving 
benzodiazepines (Table 1) and found no significant difference (χ2 = 4.39, df = 
2, p = 0.36).  
By the criteria of Schooler and Kane (19), the proportion of  TD among 
the three genotypic groups did not differ significantly (χ2 = 1.44, df  = 2, p = 
0.49). As the biological measures of expression and function of the s/s and l/s 
are similar (209), we compared the 89 patients with the genotypes (l/l and s/s) 
with those of the l/s genotype and again found no significant difference (χ2  = 
0.02, df = 2, p = 0.88). The number of patients in our study provides a power 
of 80% with 5% significance level to detect an odds ratio of 2.5 for the 
comparison of the genotypic group s/s with the combined group of l/l and l/s. 
  
DISCUSSION 
A limitation of our study was that our assessment could diagnose 
cases of probable TD and not persistent TD which required a second 
assessment 3 months later. Therefore we could have included some false 
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positives. We have also not examined the AIMS scores for the different body 
regions within each of the genotypes as the number in each group would have 
been too small to allow for any meaningful analysis. Dyskinesia of the 
different body regions may represent subtypes of TD with different 
pathophysiological and genetic mechanisms as suggested by Macciardi et al. 
(210) who found a positive association between the Ser9Gly polymorphism of 
DRD3 and oro-facial TD but not those involving the limbs or trunk. Muscettola 
et al. (211) also reported that oro-facial TD was less frequently associated 
with parkinsonism.  
 
To date, there have been a few investigations on the association of the 
5-HTTLRP polymorphism with personality traits and affective disorders. Lesch 
et al. (212) reported an association between this polymorphism and anxiety-
related traits although this was not replicated by subsequent studies (213,214) 
except in Japanese (215,216).  No association was found with bipolar 
affective disorder (217,218). The result of this study suggests that the 5-
HTTLPR polymorphism is not involved in the pathophysiology of TD in 
Chinese patients with schizophrenia.  
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Table 1. Genotypes and demographic and clinical features of sample  
 
































            
l/l 19 (10) 14 5 56.0 
(8.6) 
33.8 (8.0) 422.8 (679.9) 16.9 (10.4) 4  (21) 5.3 (4.9) 3.7 (3.3) 11 (58) 
            
l/s 70 (37) 57 13 50.8 
(10.2) 
27.5 (9.1) 583.6 (605.6) 16.9 (9.1) 24 (30) 7.3 (6.9) 3.1 (3.6) 31 (44) 
            
s/s 99 (53) 78 21 51.6 
(9.5) 
29.9 (8.8) 645.0 (679.4) 18.9 (9.9) 23 (22) 5.9 (6.0) 3.1 (3.6) 39 (39) 











SMOKING AND TARDIVE DYSKINESIA: LACK OF INVOLVEMENT OF 





































Aims: (i) To establish the association of cigarette smoking with tardive 
dyskinesia (TD) among Asian patients with schizophrenia and (ii) to evaluate 
the role of CYP1A2 polymorphism in TD among patients of Chinese descent. 
Method: Two hundred and ninety one patients diagnosed with schizophrenia 
according to the DSM IV criteria, with well established smoking history were 
included in the study. Dyskinesia was assessed by the Abnormal Involuntary 
Movement Scale and TD by the criteria of Schooler and Kane. Demographic 
and clinical data including current neuroleptic dosages as well as history of 
smoking habits was collected.  One hundred and three patients of Chinese 
descent and with a history of smoking were subsequently genotyped for 
CYP1A2. 
Results: Forty-three of the 104 patients with a history of smoking were 
diagnosed to have TD (41.3%). The prevalence of TD was significantly higher 
among the smokers as compared to the non-smokers (χ2 = 5.57, p= 0.018). 
Logistic regression using TD as the dependent variable revealed smokers to 
be at a significantly higher risk of TD (p<0.005). Genotyping for CYP1A2 
among smokers of Chinese descent revealed no significant differences in the 
genotypic or allelic distribution between those with and without TD. 
Conclusions: Consistent with other studies we found a significantly higher 
rate of TD among the smokers, however our study did not demonstrate an 
association between the C→A genetic polymorphism of CYP1A2 with TD. 
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The prevalence of smoking in patients with schizophrenia has been 
found to be higher than that of the general population (219-221). It has been 
suggested that smoking may lead to a number of consequences including 
more severe psychotic symptoms (222), higher dose of antipsychotic 
medication being prescribed (223-225) and increasing the risk of tardive 
dyskinesia (TD) (226-228).   
The pathophysiology of TD remains to be fully elucidated with genetic 
factors being implicated as suggested by the interindividual variation in 
vulnerability (229).  A particular line of investigation has focused on the 
genetic contribution to the pharmacodynamic and pharmacokinetic aspects of 
antipsychotic medications. These include genetic association studies of the 
dopamine (D2 and D3) receptors (172,230) and cytochrome P450 2D6 
(CYP2D6) (231-233). Recently, Basile et al (233) found an association 
between a C → A genetic polymorphism of the CYP1A2 gene and TD, with 
the C/C genotypes being associated with greater TD severity than the A/C or 
A/A genotypes among patients who are smokers. The authors suggested that 
CYP1A2 which is present at a greater concentration in the liver than CYP2D6, 
would assume greater importance in the metabolism of antipsychotics 
following the saturation of the CYP2D6 with chronic antipsychotic treatment. 
Pharmacokinetic studies which indicate that variability in the CYP1A2 activity 
occurs only in smokers (234) suggest that this polymorphism would assume 
functional importance only in smokers. The halogenated hydrocarbons are 
potent inducers of CYPs in the CYP1 gene subfamily (235) and the plasma 
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concentration of most first generation antipsychotics (including fluperazine 
and chlorpromazine) is significantly reduced by smoking (236,237). This being 
the case, it would provide a possible explanation for the association between 
smoking and TD.  Basile et al. (233) proposed another mechanism wherein 
neurotoxic antipsychotic metabolites produced by alternative metabolic 
pathways due to the lowered CYP1A2 activity in patients with the C/C 
genotypes may contribute to TD.  
The aims of this study were: 
1. To establish the association of cigarette smoking with TD among patients 
with schizophrenia. 
2. To examine the role of the CYP1A2 polymorphism in TD among patients 
of Chinese descent. 
 
METHOD 
Patients hospitalized in the long-stay wards of Woodbridge Hospital 
who were willing to give informed consent were recruited.  
Two hundred and ninety-one patients diagnosed with schizophrenia 
agreed to take part in the study. The smoking habits of the patients were 
established by interviewing the patients and obtaining corroborative history 
from the nursing staff; cases where conflicting histories were obtained, were 
not included in the study. 
In the second part of the study, which involves genotyping for the CYP 
1A2 gene polymorphism, only patients of Chinese descent who were smokers 
were invited to participate. Only those who gave written consent were 
recruited for the study.  
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Genetic Analysis 
Venous blood was collected in EDTA tubes and genomic DNA was 
extracted with QIAamp Blood Kit (Qiagen GmbH, Hilden, Germany). The 
region of interest was first amplified by polymerase chain reaction as 
previously described (17).  PCR products were incubated with the restriction 
enzyme Bsp120I according to manufacturer’s instructions (New England 
Biolabs, USA). Resulting products were detected by ethidium bromide 
staining following electrophoresis on a 2% agarose gel. 
Statistical Analysis 
 Mann-Whitney U test was used to examine the differences between 
those with and without TD as the variables did not have a normal distribution 
pattern. Differences in demographic characteristics, current antipsychotic 
dose, AIMS score and SARS amongst the different genotypes were 
determined using the Kruskal-Wallis test. Probability values of 0.05 or less 
were regarded as statistically significant. Tests for differences of allele 
frequencies, genotypes and other categorical analysis were performed using 
the chi square test. To control for the influence of other variables, logistic 
regression was applied to the factors associated with tardive dyskinesia. 
 
RESULTS 
The main demographic and clinical variables of the 291 patients (220 
males and 71 females) are listed in Table 1. Patient age ranged from 23 to 83 
(mean = 52.7, SD = 10.3) years. Of these, 288 (99.0%) were Chinese, and 3 
(1.0%) were Malays. There was no gender difference (χ2 = 0.85, p = 0.35) 
between those with TD and those without TD. Those with TD were 
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significantly older (p < 0.005, Mann-Whitney U Test) and receiving a lower 
daily dose of antipsychotics than those without TD (p < 0.005, Mann-Whitney 
U Test). We found a significant difference in the frequency of TD between 
smokers and non-smokers (χ2  =5.5, p= 0.018). 
Among the 104 (32.3%) patients who smoked, 92 were males and 12 
were females (mean age = 51.8 ± 10.4 years). Within this group of patients, 
there were also significant differences in age and daily antipsychotic dose 
between those with TD compared to those without (Table 1). The distribution 
of the alleles and genotypes for the patients who were smokers is presented 
in Table 2. Testing for Hardy-Weinberg equilibrium showed that the genotypes 
frequencies did not deviate significantly from the frequencies expected under 
random mating conditions for those with TD (χ2 = 0.19, df = 1, p = 0.67); and 
those without TD (χ2 = 0.33, df = 1, p = 0.56). Genotype frequencies did not 
differ significantly between those with and without TD (χ2 =0.90, p= 0.63). The 
allele frequencies also did not differ significantly between those with and 
without TD (χ2 = 0.38, p = 0.56). The median AIMS score also showed no 
significant difference between the three genotypes (χ2 = 1.8, p = 0.40). The 
genotypes did not differ significantly in other demographic or clinical 
characteristics. 
On performing a logistic regression, with TD as the dependent variable 
and age, antipsychotic dose, cumulative exposure to antipsychotics, smoking 
status and genotype, as the independent variables. Age (p<0.05) and 
smoking status (p<0.005) remained independently associated with a higher 
risk of TD while daily antipsychotic dose was associated with a significantly 
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(p<0.005) lower risk of TD.  Odds ratio of developing TD for smokers relative 
to non-smokers was 2.7 (95% CI = 1.5-5.0). 
 
DISCUSSION 
Consistent with other studies (226,227), we have found a significantly 
higher rate of TD among the smokers. Although there were also negative 
reports (223, 235, 236), the smokers had significantly higher dose of 
antipsychotic medication which could have masked the presence of dyskinetic 
movements in those studies (228).  
Suggested mechanisms for the association of smoking and tardive 
dyskinesia include increased dopaminergic activities from nicotine, leading to 
nigrostriatal hypersensitivity of dopamine; and neurotoxicity from the free 
radicals in cigarette smoke causing damage to catecholaminergic neurons in 
the basal ganglia (238,239). Smoking also increases the risk of 
cerebrovascular pathology which in turn may lead to increased vulnerability 
for developing TD (240). Consistent with the findings of Schulze et al. (241) 
and Shimoda et al. (242), we did not find any difference in the genotypic or 
allelic distribution between those with and without TD, and no significant 
difference was observed in the mean AIMS score of the different genotypes. 
However, there were differences in antipsychotic dose and duration of 
exposure in subjects with and without TD – which could have confounded our 
results. In patients who are smokers, smoking-induced CYP1A2 activity 
resulting in lowered plasma antipsychotic levels, may in turn lead to 
inadequate control of psychotic symptoms. This situation may lead to more 
antipsychotics being prescribed and these patients may consequently be 
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exposed to higher plasma antipsychotic levels. In our study, those with TD 
were receiving a lower daily antipsychotic dose and this may be due to a 
deliberate dose reduction following the diagnosis of TD.  On the other hand, 
subjects without TD had a significantly higher daily antipsychotic dose which 
could have masked any dyskinetic movements among those who were 
assessed not to have TD although this was unlikely as there was no 
significant difference in the mean Simpson-Angus Rating Scale score 
between those and without TD.  
A limitation of this study is the lack of a structured interview to establish 
our diagnosis of schizophrenia. Another limitation is that we did not quantify 
the amount of smoking, which may have confounded our study as a positive 
correlation between CYP1A2 activity and the exposure has been reported 
(243). Our patients also received a variety of typical antipsychotics with some 
being prescribed more than one type of antipsychotic (152). The diversity of 
antipsychotics is an important consideration as the role of CYP1A2 in the 
disposition of antipsychotics is limited to a few - clozapine, haloperidol, 
chlorpromazine and olanzapine (244).  
Our study did not demonstrate an association between the C→A 
genetic polymorphism of CYP1A2 with TD; we however did not investigate the 
role of a G→A polymorphism which is associated with decreased activity of 
the CYP1A2 in Japanese subjects (245). Such studies should however be 
limited to patients who have been on antipsychotics that are substrates for 
CYP1A2. 
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Table 1.  Clinical and Demographic Characteristics of Patients 
 








(n = 196) 
Patients with 
TD 












(n = 135) 
 






   
    Male 
    Female 
   75                         145 
   20                           51 
         38                          54 
           5                            7 
         37                          91                
         15                          44 
  
Mean ± SD 
 
Mean ± SD 
 
Mean ± SD 
 
Mean ± SD 
 
Mean ± SD 
 




57.7 ± 9.5 
 
50.3 ± 9.8 
 
55.3 ± 10.6 
 
49.2 ± 9.5 
 
59.7 ± 7.9 
 
  50.7 ± 10.0 
Cumulative exposure to 
antipsychotics (yrs) 
17.9 ± 10.2 16.0 ± 9.6 17.7 ± 10.8 13.0 ± 8.3 18.0 ± 9.6  17.3 ± 9.8 
Daily dose of antipsychotics 
(CPZ mg eqv)* 
279.1 ± 299.1 752.2 ± 650.1 323.6 ± 344.4 841.0 ± 671.4 242.3 ± 253.4  712.0 ± 638.7 
Daily dose of diazepam (mg) 1.73 ± 3.75 1.94 ± 3.87 2.0 ± 3.8 1.9 ± 3.8 1.5 ± 3.7  2.0 ± 3.9 
Simpson-Angus Rating Scale 
score 
6.22 ± 5.99 5.99 ± 5.95 5.9 ± 6.0 5.7 ± 5.6 6.2 ± 5.9 6.0 ± 6.0 
* p<0.005, Mann-Whitney U test (for all patient with TD vs. without TD; smokers with TD vs.  without TD; non-smokers with TD vs. Without TD) 
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Table 2.  Genotypic and Allelic Distribution With Relation to TD Status and AIMS Score 
 
 Genotypic distribution                                          Allelic distribution 
 
 
                                A/A genotype  A/C genotype  C/C genotype      P value                     Allele A    Allele C    P value 
 
 
Smokers, n = 103  
TD+, n = 43   17    19     7                53          33 
 
TD-, n = 60     25    29     6              0.63a                 79                 41           0.56a 
 
AIMS score (median)             1    1   2                      0.40b 
AIMS score (mean ±SD)  2.0 ± 2.7         2.6 ± 3.3        2.7 ± 2.7   0.19c 
a Chi square Test 
b Kruskall-Wallis Test 
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This dissertation represents a body of work which endeavored to 
establish the prevalence of TD and to identify some of the associated risk 
factors.  These studies were carried out among patients with schizophrenia – 
a devastating illness of disturbed thinking and hence capacity to informed 
consent may be compromised. Although patients with schizophrenia as a 
group show greater level of impairment in this aspect than non-ill comparison 
subjects, or patients with general medical illness, there is considerable 
variation, and many patients score in the same range as comparison subjects 
– hence the presence of a diagnosis per se is not an indication that a subject 
is unable to give competent consent (246). There is still much to be known 
about how best to assess this capacity. Although there are instruments like 
the MacArthur Competence Assessment Tool for Clinical Research (MacCAT-
CR) to assess for decisional capacity, a recent review of these instruments 
concluded that the various capacity assessment tools should undergo further 
empricially based development as well as testing with a variety of populations 
(247). In view of the lack of a locally validated instrument, the decisional 
capacity of the patients for this series of studies were assessed by the 
clinician-investigators who were all experienced psychiatrists. This was based 
on the clinician’s assessment of patient’s ability to reason, to comprehend, to 
appreciate, decide and to communicate that decision. Based on these criteria, 
a large number (more than 50%) of patients were deemed to be not mentally 
capable of informed consent. We need not use educational approaches to 
improve the patient’s decisional performance as have been show by small-
scale studies (248, 249).  
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 The rate of TD is much higher than those previously reported in other 
studies involving Asian patients. While this difference may be due to 
differences in age and medication exposure - which underscores the 
likelihood that variation in rates across studies may be due to differences in 
methodologies, medication variables (e.g. dose and duration of exposure), the 
amount of evidence to date does not rule out the possibility that genetic 
factors may account for some of the variance in rates in ethnic groups. 
With regards to our examination of some the putative risk factors 
(Table 1), some of our findings replicated those of other studies (3,11,24,28) 
of positive association with factors like advanced age and smoking. However, 
we did not find any gender differences which is in contrast to other reports (4), 
nor did we find any difference between the 2 major races in Singapore: 
Chinese and Malays whose rates were 40.5% and 29.0% respectively which 
were not statistically after adjusting for age, and these rates were not lower 
than rates reported in Western populations. Neither did we find diabetes 
mellitus nor a higher fasting blood sugar level to be associated with TD, 
however we had examined these in a cross-sectional manner and did not 
factor in the duration of these abnormalities which may be a crucial 
consideration. 
The pathophysiology of TD is not completely understood. A genetic 
component in the susceptibility to TD is suggested by clinical reports of 
aggregation of TD cases in families (72,165,166). However, the mode of 
inheritance is not known. 
One suggested mechanism for the pathophysiology of TD is the 
upregulation of post-synaptic dopamine D2 receptors in the nigrostriatal 
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dopaminergic tract (which is pivotally involved in the regulation of motor 
behaviour) from long term treatment with antipsychotics (9), and which leads 
to nigrostriatal dopaminergic overactivity.  Considering the putative role of 
genetics alongside this hypothesis, we have used a candidate gene approach 
and examined the role of 2 subtypes of dopaminergic receptors 
polymorphisms in susceptibility to TD: D2 receptor (DRD2) and D3 receptor 
(DRD3). For the former, the Ser311Cys polymorphism was examined and 
found not to be associated with TD. Other reports have similarly reported a 
negative association (75,171). It should, however, be noted that the DRD2 
gene is large – more than 250-kb in length – and therefore difficult for any one 
investigation to examine all the polymorphic sites.  
Our findings support a small but significant contribution of the DRD3 in 
particular with the Ser9Gly polymorphism and with increased age. Segman 
and Lerer (171) suggested that genetically based variations in receptors might 
become more functionally relevant at an older age when receptor reserve is 
reduced for reasons related to the aging process. Another possible 
explanation is that older patients will tend to have a greater cumulative 
exposure to antipsychotic drugs.  
Several lines of evidence implicate brain serotonergic systems as 
possibly modifying susceptibility to express TD.  Dorsal raphe serotonergic 
projections inhibit dopaminergic neuronal activity through 5-HT2A receptor 
activation (52).  5-HT2A antagonists have been shown to augment 
endogenous striatal dopamine release in vivo (184,187,188). Using the same 
candidate gene strategy in our examination of the dopamine receptors, we 
targeted the 5-HT2A receptor for which a number of polymorphisms have been 
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described (191,250-252), and the transporter gene for serotonin (5-HTTLPR). 
We did not find any association with the latter but found an association of the 
T102C polymorphism in the 5-HT2A receptor gene with TD. We chose to target 
this particular polymorphism even though it is an intronic variant that does not 
code for a change in the structure of the receptor protein, because an earlier 
study which reported a positive association (172) – a findings which needed 
replication. Furthermore, this polymorphism is in close LD with an –1438G 
polymorphism in the HTR2A promoter (172). The silent T102C site could 
reflect the impact of the promoter site through LD and evidence that the 
T102C polymorphism may directly affect expression of 5-HT2A mRNA and 
protein has been reported (253). The HTR2A T102C polymorphism has also 
been associated with schizophrenia, clozapine response in different studies 
(254) and therefore may be a genetic marker for a subtype of schizophrenia 
that is characterized by increased susceptibility to TD or reduced 
responsiveness to antipsychotic drugs. The latter situation would result in 
patients receiving higher doses of antipsychotics for longer periods, thus 
being exposed to increased risk for TD on this basis.   
As cumulative exposure to antipsychotic is a risk factor for TD, any 
genetic variants affecting the metabolism of antipsychotic may change 
pharmacokinetic factors, such as plasma drug concentration and half-life. 
Pharmacokinetic pharmcogenetic studies have focused on polymorphisms in 
the liver cytochrome P450 isoenzymes that metabolise most of the 
antipsychotics. The most extensively investigated gene is CYP2D6, which 
encodes debirsoquine hydroxylase. The reported findings in the extant 
literature have been largely negative (255). We, therefore, decided to focus on 
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the CYP1A2 gene as it has a higher capacity to metabolise drugs like 
haloperidol and therefore may be the most important determining factor of 
steady-state antipsychotic drug levels (256). However, we found no such 
association when the C→A polymorphism of this gene was examined. 
The dopamine hypersensitivity hypothesis, however, has its limitations: 
animal studies do not parallel clinical observations as DA supersensivity in 
rats develops rapidly and persist for only a short period after cessation of the 
drug, this sensitivity also declines after “desensitization” with DA agonist, but 
these drugs are not effective in treating TD in humans (257). The inadequacy 
of the DA hypothesis has led to the consideration of other pathophysiological 
models.  
Another hypothesis is the neuronal degeneration hypothesis of TD 
(258). Evidence for this comes preclinical studies when the administration of 
first-generation antipsychotics are associated with increased free radical 
activity and behavioural changes suggestive of tardive dyskinesia, and which 
are preventable by antioxidants like Vitamin E (259,260). Free radical and 
excitatory mechanisms lead to neurotoxicity and cell death, particularly of the 
catecholaminergic neurons in the basal ganglia. Smoking may lead to both 
dopamine hypersensitivity and free radicals formation. Antipsychotic 
medication by blocking dopamine receptors caused a secondary increase in 
dopamine synthesis and a corresponding increase in dopamine synthesis - 
which in the presence of transition metals like iron, copper and manganese 
produce highly reactive hydroxyl radicals. These can overwhelm the 
antioxidant brain defences, and cause damage. As antipsychotics lead to the 
accumulation of iron in the basal ganglia, this could be neurotoxic through the 
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free radical mechanisms (258). Peripheral iron level which was examined in 
this dissertation, was not found to be associated with TD. However, serum 
iron indices may not be an accurate reflection of brain iron due to the 
protective effect of an intact Blood-Brain Barrier. A recent review (258) of both 
preclinical and clinical data support the possibility that neurotoxic free radical 
production may be an important consequence of antipsychotic treatment, and 
that such production may be related to the development of TD.  
TD is therefore not only polygenic but there are other various 
interrelationships that may be involved in its pathogenesis and 
pathophysiology. An attempt to incorporate these various mechanisms in a 
synthesis is presented in the Figure 1.  
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Figure 1. Pathogenetic mechanisms of tardive dyskinesia (see details in text). In 
summary, there are some individuals who are at risk e.g. those with a genetic 
vulnerability, who are smokers, of advanced age, and with history of protracted use 
of antipsychotics, which by their different mechanisms and interaction with each other 
lead to TD. The high level of catecholamine turnover and oxidative metabolism in the 
stratium lead to free radicals production resulting in neurotoxicity and cell death of 
the striatal neurons and the clinical manifestation of TD.  
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Methods Issues 
A critical issue particularly for genetic study is the reliability and validity 
of the phenotype being studied. We have used a structured instrument for 
assessing TD and each patient was assessed at least twice at different time 
which enabled us to make a diagnosis of definite TD. We have regarded TD 
as a unitary entity although more recent work has demonstrated its diverse 
clinical manifestations. There now appears to be two major subtypes: 
orofacial or limb-truncal presentations (211,261); with different clinical and 
demographic risk factors being associated with each subtypes and possibly 
with different genetic architecture. 
Reliability of the clinical diagnosis is a crucial issue in schizophrenia 
research and studies using technologies like molecular genetics or brain 
imaging re-emphasized the importance of careful and precise definition of the 
disorder. Efforts to increase this reliability have been mainly through the use 
of the 2 systems of diagnostic criteria at present: the WHO-ICD and the 
American Psychiatric Association (APA)- DSM. There were considerable 
variance between the earlier ICD-9 and DSM-III, where certain specific areas 
of classification in ICD-9 did not seem sufficiently detailed for clinical and 
research use, the glossary of ICD-9 was also viewed to be less than optimal 
in that it did not made use recent major methodological developments as 
specified diagnostic criteria and multiaxial approach to evaluation (262).  
When work began on ICD-10, a task force was appointed by APA to 
work in parallel with the development of ICD-10 and to ensure greater 
compatibility. The DSM-IV criteria which have been improved upon (as 
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compared to the previous DSM-III) with weight given to the evidence accrued 
from decades of psychopharmacological treatment that negative or deficits 
are defining core features rather than the florid psychotic symptoms. 
Research done for the Task Force on DSM-IV has shown that deficit 
symptoms can be reliably defined and therefore be considered as core 
features of the disorder (262). Near perfect agreement was demonstrated 
between the ICD-10 and DSM-IV diagnoses, including the high reliability of 
the clinical diagnosis of schizophrenia (263).  
The population-based association studies we used have been a fruitful 
approach for locating predisposing molecular mechanisms largely because 
targets of drug action pose direct hypotheses implicating candidate genes. 
However, such case-control designs require large samples if they are to 
identify and replicate small gene effects. Our negative findings may be limited 
to the levels of association that could be excluded given the size and 
statistical power of the samples. 
 
Future directions 
First, there is a need to further refine the phenotype of TD and 
delineate more distinctly the subtypes – presently, the orofacial or limb-truncal 
subtypes, along demographic, clinical and genetic lines. 
Second, the genetic part of this present dissertation have focused one 
or two polymorphisms in each gene; presently with the availability of more 
sophisticated and powerful genotyping technology as well as the availability of 
SNP databases, future studies could type for multiple single nucleotide 
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polymorphisms (SNPs) across the entire length of the candidate gene and 
examined for gene-gene interaction in large samples. A potential method is to 
organize these SNPs within a gene, or a region of the genome, into 
haloptypes which provide more comprehensive examinations of single genes 
and may provide increased power to detect pharmacogentic associations if 
rare alleles are contributing to phenotypic differences (264). 
Third, the candidate gene approach could also be applied to establish 
the veracity of the free radical hypothesis in the light of the genotyping of the 
gene of manganese superoxide dismutase (MnSOD) (265) – an enzyme 
which catalyse reactions in which free radicals or free radical-producing 
substances are altered to form nonradical structures.  
 Fourth, the combined use of genetic technique and brain imaging 
technology would shed more insight as suggested by a study of positron 
emission tomography (PET) imaging of patients who were gentoyped for the 
Ser9Gly variant of DRD3 (266) and scanned before and after treatment with 
haloperidol. The patients with the glycine/glycine genotype showed greater 




Tardive dyskinesia (TD) is a potentially irreversible movement disorder 
that affects 20-50% of patients receiving long-term first generation 
antipsychotic treatment. The use of second generation (atypical) antipsychotic 
drugs which seem to have a lower propensity to induce TD is now common 
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(267,268). The risk of TD with the second generation antipsychotics were 
examined in a systematic review (269). The major findings of this systematic 
review) from 11 long-term studies involving 2,769 patients seem to support 
the expectation that second-generation antipsychotic agents have a reduced 
risk for tardive dyskinesia, compared with first generation antipsychotics 
(Table 2). The weighted mean annual tardive dyskinesia incidence for 
second-generation antipsychotics was only 0.8% which is considerably lower 
than the mean annualized tardive dyskinesia incidence of 5.4% for haloperidol 
in the three studies that included haloperidol as an active comparator.  The 
rates for haloperidol are consistent with 1-year incidences of about 5% for 
first-generation antipsychotics.  
But first generation (typical) antipsychotic agents are still extensively 
prescribed - primarily for economic reasons – in not just developing countries 
(270) but also in developed economies in East Asia like Japan, Korea, Hong 
Kong and Singapore (271), and as suggested from our findings, the risk of TD 
might be any less among Asians as compared to Westerners. The role played 
by ethnicity has yet to be fully elucidated. There may still be ethnic differences 
in the pharmacokinetics and pharmacodynamics of antipsychotics 
medications (either from diets or genetic factors) which may either increase or 
decrease the risk of TD.  Furthermore, there is growing concern about the 
adverse effects of atypical antipsychotic drugs on body weight and glucose-
lipid metabolism (272). Hence, the problem of TD will continue to be relevant, 
and any practical means of identifying those at risk of developing TD would be 
of immense clinical importance.   
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We have identified a number of risk factors for TD and it could help 
identify those at risk which would allow for closer monitoring and alternate 
treatments, as well as help direct the development of safer and more specific 
antipsychotic drugs.  
While the contribution of each individual gene to risk for expression of 
TD is probably relatively small, these genes could, nonetheless, putatively 
form the basis for a pharmacogenetic test to predict risk for TD. As each of 
the identified risk factor has low predictive value and does not have clinical 
utility, it should be considered in the context of a panel of genetic 
polymorphisms that have been associated with TD.  Such a test would need 
to take into account complex interaction among different variants. This 
dissertation also found that increased age and smoking are risk factors and 
should be considered in the design and interpretation of pharmacogenetic 
studies and for the ultimate development of pharmacogenetic tests for TD 
which would enable clinicians to have the option of prescribing either first or 
second generation antipsychotics based on the ability to identify those at high 
risk for developing TD.  
It is also possible that genetic susceptibility to TD may indicate a more 
specific phenotype of schizophrenia with a selective prognostic course and 
drug response profile, and which may prove instrumental for refining the 
phenotype definition in genetic studies of schizophrenia. 
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Risperidone 1.4 322 — 0.0 
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Table 1: Reported Minimum Effective Fixed Doses and Chlorpromazine 













Haloperidol 4 2 
 
Risperidone 4 2 
 
Olanzapine 10 5 
 
Quetiapine 150 75 
 
Ziprasidone 120 60 
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PSYCHOPATHOLOGY OF 2 PATIENT SUBJECTS 
 
Patient # 242 
 
This patient was first admitted to Woodbridge Hospital in 1976 after being 
brought by the police for assaulting his family members in his belief that they 
wanted to harm him. 
From the history obtained subsequently, the patient had a change of 
behaviour which went back to at least 2 years prior to this admission. For 
some unspecified reason, he stopped work and became socially withdrawn 
and became estranged from his wife.  
He would at times talk to himself and would gesticulate without any reason. 
He later developed paranoid ideas about a certain person and this paranoid 
ideation later extended to his family –expressing odd ideas of them trying to 
kill him by “turning his eyes blue”. He also refused to go out on out as he 
feared that he would be harmed by some unknown persons. 
He had an older brother who was described to be “mentally unwell” (no 
verification of this was possible from any documentation) and had later killed 
himself. 
There was no history of any use of psychoactive substances. He had no 
clinically significant medical condition. 
On that first admission, it was documented in the medical records that patient 
was unkempt and was relevant to questioning. His affect was noted to be 
appropriate. He also admitted to having auditory hallucinations of the 
command type. These “voices” had commanded to kill himself. There were no 
other hallucinations. There were prominent paranoid delusions of a rather 
bizarre nature, there was also passivity. These hallucination, delusion and 
passivity (he felt there was an external agency controlling his thoughts and 
physical movements) were at least 12 months in duration. 
Other than mild irritability of his mood, there was no depressive of 
hypomanic/manic symptoms. There was no obvious cognitive impairment, 
and he had no insight that he was suffering from a mental illness. The 
laboratory investigations including full blood count, urea/electrolytes, thyroid 
function test were within normal range. 
 
When patient was assessed for this study on 17 March 1999, he was relevant 
and forthcoming. There was mild blunting of affect, and he still had some 
residual auditory hallucination although the frequency and intensity had 
diminished by his own account. 
He had not returned to any form of employment since his illness. 
 
This patient had auditory hallucinations, paranoid delusions, passivity, as well 
as a period of social and vocational deterioration before the onset of the 
psychotic symptoms – all of which are diagnostic of schizophrenia according 
to DSM-IV. 
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Patient # 265 
 
This patient was first admitted to Woodbridge Hospital in 1988. He was 
brought in by his family after presenting with at least one-year history of a 
change in his behaviour – becoming rather withdrawn, then increasing more 
avolitional: stopping work and subsequently even the point of neglecting his 
self-care. His family had also reported the patient to talk rather oddly and 
incoherently, and would at times mutter to himself.  
 
His childhood history was unremarkable: he went to regular school – attaining 
3 passes in his “O” levels examination, had friends, and was in the school 
basketball team. He completed his National Service with no problem, and 
started work as a technician upon his discharge from the army.  
 
His maternal grandmother was said to be “mentally unwell” (no verification of 
this was possible from any available documentation and the family could not 
give any description of her behaviour beyond this). There was no history 
suggestive of any depressive of hypomanic/manic symptoms. There was no 
history of any use of psychoactive substances. He had no clinically significant 
medical condition. 
 
The mental state examination on that first admission had documented that the 
patient was unkempt with evidence of poor personal hygiene, and had formal 
thought disorder. There was also auditory hallucination of the commentary 
type (these voices commented on his action as he went about his daily 
activities) which had apparently started at about the same time as his change 
of behaviour. No delusions were elicited. There was no obvious cognitive 
impairment, and he had no insight that he had a mental illness. The laboratory 
investigations including full blood count, urea/electrolytes, thyroid function test 
were within normal range. 
 
When patient was assessed for this study on 19 March 1999, his affect was 
noted to be blunted and there was some poverty of his content of speech. 
However, he could answer to the point most of the times although infrequently 
there was some derailment of his thoughts. He was oriented to time, place 
and person. His affect was blunted. There was no more hallucination, nor did 
he have any delusion. 
He had been staying in the long-stay ward of Woodbridge Hospital since 
1997. 
 
This patient had auditory hallucinations, disorganization of thought, and 
negative symptoms (avolition, blunting of affect) that were associated with 
deteriorated functioning in work and relationship of more than 6 months 
duration – features which fulfilled the diagnosis of schizophrenia according to 
DSM-IV criteria. 
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